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ABSTRACT 
 
The key player in human innate immune response is the complement system that 
attacks microbes and foreign particles invading human body. Complement cascade 
can be activated through three pathways, the classical, alternative, and lectin 
pathways. The classical and lectin pathways are activated by recognition of nonself 
structures while the alternative pathway is constantly in a slightly active stage and 
is triggered on surfaces that are missing self signals. Surface-deposited 
complement components act as opsonins for phagocytes while chemotactic and 
anaphylatoxic components released upon complement activation induce 
phagocyte recruitment, phagocytosis and the inflammatory response. The 
components of the late stage of the activation cascade form lytic transmembrane 
complexes on the surface of the target. 
Complement activation is regulated by host surface bound as well as fluid phase 
molecules that act on several steps during the cascade. Factor H (CFH) is an 
important fluid phase regulator. It is an elongated protein consisting of 20 domains 
where the four most amino-terminal domains are responsible for the regulatory 
activities. A common polymorphism Y402H in CFH that is located in the domain 
seven has been shown to be associated with age-related macular degeneration 
(AMD). Several pathogenic microbes capture CFH on their surface from host 
plasma inhibiting the function of the complement system on the microbial surface. 
The surface exposed M protein of the pathogenic bacterium, Streptococcus 
pyogenes, binds CFH via the domain seven. The highly variable region of the 
protein confers to serotype specificity and on the basis of the gene region coding 
for the hypervariable part of M protein the bacteria can be divided into over 150 
different emm types.  
The aims of this thesis were to analyze the effects of CFH binding on microbial 
complement evasion in vivo and in vitro and to analyze how genetic variation in 
CFH affects S. pyogenes survival and host infection susceptibility. It was shown that 
Loa loa microfilariae isolated from patient blood carried host CFH and C4BP on 
themselves. The complement components deposited on microfilariae surface in 
vivo and in vitro were inactive indicating that the microfilariae evade complement 
attack using surface bound CFH and C4BP.  
Most of the S. pyogenes strains studied were found to bind CFH and a recombinant 
CFH fragment consisting of domains 5-7 (CFH5-7) in vitro. Binding of CFH and 
CFH5-7 to 38 studied S. pyogenes strains was variable and the binding affinity 
showed significant inverse relationship with formation of complement activation 
markers in serum. When a CFH5-7 fragment lacking the cofactor active domains 
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was incubated with the CFH binding strains in an in vitro survival model the 
multiplication of the bacteria was significantly decreased showing that CFH binding 
via the domain seven is crucial for survival of S. pyogenes.  
CFH was isolated from human plasma obtained from donors that were genotyped 
homozygous for the Y402H polymorphism. The two allotypes bound differentially 
to the surface of the studied S. pyogenes strains and the diminished binding of the 
allotype CFH(402H) resulted in a significant decrease in multiplication of the 
bacteria in an in vitro survival assay. On the basis of these results it seems that the 
residue 402Y is crucial in S. pyogenes-CFH interaction and that the Y402H 
polymorphism affects opsonization and phagocytosis of the bacterium. 
The Y402H (C1277T) genotype was analyzed from patients with history of 
erysipelas or recurrent tonsillitis (n=487) and from 455 control subjects. 
Comparison of the allele and genotype frequencies between the patients and 
control subjects suggests that the polymorphism is associated with susceptibility to 
streptococcal infections.  
In conclusion, the results show that complement evasion by binding of 
complement regulators occurs both in vitro and in vivo and that within the S. 
pyogenes species CFH binding via the domain seven is a common way to evade 
complement attack and to enhance microbial survival in the host. The ability to 
capture host CFH varies within different S. pyogenes strains as well as within 
different isolates and it is likely that the affinity of CFH binding determines the 
ability of bacteria to evade the complement attack. It also seems that the CFH 
Y402H polymorphism affects S. pyogenes survival in vitro and this finding probably 
also has clinical relevance since the studied polymorphism suggests an association 
with host susceptibility to streptococcal infections erysipelas and recurrent 
tonsillitis.  
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TIIVISTELMÄ 
 
Komplementtijärjestelmä on keskeinen luontaiseen immuniteettiin kuuluva tekijä, 
joka toimii ensimmäisenä puolustuksena isäntään tunkeutuvia mikrobeja vastaan. 
Se voi aktivoitua sekä tunnistamalla vieraita rakenteita klassisen- tai lektiinitien 
kautta että ilman mitään spesifiä tunnistuskohdetta oikotieaktivaation kautta. 
Komplementtiaktivaation käynnistyttyä vieraan kohteen pinnalla, aktivaatio 
etenee peräkkäisten reaktioiden sarjana. Reaktiosarjan aikana pilkkoutuneista 
proteiinin paloista osa vapautuu plasmaan toimien houkuttimina ja aktivoijina 
luonnollisen immuniteetin puolustussoluille. Tietyillä kohteen pinnalle 
kiinnittyneillä proteiinien osilla on puolestaan kyky opsonoida eli kuorruttaa 
kohde, jotta fagosyytit voisivat tunnistaa sen. Aktivaatiokaskadin edetessä loppuun 
kohteen pinnalle voi muodostua solukalvon läpäiseviä komplekseja. 
Komplementin oikotie aktivoituu herkästi minkä tahansa kohteen pinnalla ja voi 
olla tuhoisa elimistön omillekin soluille ellei sitä säädellä tehokkaasti. Elimistömme 
omia rakenteita suojataan komplementin säätelijäproteiineilla, joita löytyy sekä 
plasmasta liukoisena että omien solujen solukalvoihin kiinnittyneinä. Faktori H 
(CFH) on plasmassa liukoisena esiintyvä pitkänomainen komplementin 
oikotieaktivaatiota säätelevä proteiini, johon kuuluu 20 samankaltaista osaa eli 
domeenia. Neljä ensimmäistä amino-terminaalista domeenia ovat vastuussa 
proteiinin säätelyaktiivisuudesta kun taas domeenissa seitsemän sijaitse CFH:n 
eräs polymorfia Y402H, joka liittyy silmänpohjan ikärappeuman syntyyn.  
Useat mikrobit, niin bakteerit, virukset, hiivat kuin vaikkapa verenkierrossa elävät 
matojen toukkamuodotkin, väistävät komplementin tuhovaikutusta kaappaamalla 
pintaansa CFH:ta. M proteiini on A-streptokokkibakteerin (Streptococcus pyogenes) 
tärkeä virulenssitekijä, joka tarttuu CFH:n seitsemänteen domeeniin. Sen 
proteiinirakenteessa esiintyy runsaasti vaihtelua eri S. pyogenes serotyyppien 
kesken ja sen hypervariaabelialueen geenisekvenssin perusteella bakteerit voidaan 
edelleen jakaa yli 150 emm-tyyppiin. 
Tämän väitöskirjatyön tavoitteina oli selvittää kuinka CFH:n sitoutuminen mikrobin 
pinnalle edistää mikrobin komplementtijärjestelmän väistöä in vivo ja in vitro, ja 
vaikuttaako CFH:n geneettinen vaihtelu ihmispopulaatiossa yksilön 
infektioalttiuteen. 
Tutkimuksen tulokset osoittavat, että potilaan verestä eristetyt Loa loa 
sukkulamadon toukkamuodot eli mikrofilariat sitovat pinnalleen CFH ja C4BP 
säätelijäproteiineja in vivo ja in vitro. Lisäksi mikrobien pinnalla havaitut 
komplementin komponentit olivat pääosin inaktivoituja ilmeisesti näiden pinnalle 
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sitoutuneiden sääteilijäproteiinien toimesta. Löydökset osoittavat, että mikrobi voi 
sitoa näitä komplementin säätelijöitä ihmisessä in vivo ja viittaavat siihen, että 
säätelijäproteiinien läsnäolo Loa loa mikrofilarioiden pinnalla estää komplementin 
tuhovaikutusta mikrobia vastaan.  
Suurin osa tutkittavista S. pyogenes kannoista sitoi pinnalleen CFH:ta ja tämän 
rekombinanttifragmenttia, joka sisälsi CFH:n domeenit 5-7 (CFH5-7). Kun eri S. 
pyogenes kantojen aiheuttamaa komplementtiaktiivisuutta mitattiin seerumissa 
komplementtiaktivaatiota osoittavien markkerien avulla havaittiin, että kantojen 
aiheuttama komplementtiaktivaatio korreloi käänteisesti kantojen kykyyn sitoa 
CFH:ta. CFH5-7 fragmentin osoitettiin myös kilpailevan sitoutumispaikasta S. 
pyogenes bakteerin pinnalla kokopitkän CFH:n kanssa, ja kun viisi tutkittua S. 
pyogenes bakteerikantaa altistettiin CFH5-7 fragmentille, niiden lisääntyminen 
kokoveressä heikkeni merkitsevästi. 
Kokopitkät CFH proteiinit, jotka eristettiin luovuttajien plasmasta, genotyypattiin 
homotsygoottisiksi Y402H polymorfian suhteen. Sekä CFH5-7 fragmentin että 
kokopitkän CFH:n sitoutuminen tutkittujen S. pyogenes kantojen pinnalle oli 
heikompaa 402H proteiinilla kuin 402Y proteiinilla. Ex vivo mallissa bakteeri 
selviytyi heikommin allotyypin CFH(402H) suhteen homotsygoottiseksi osoitettujen 
luovuttajien veressä, johtuen ilmeisimmin CFH:n heikommasta sitoutumisesta 
bakteerin pinnalle. 
Kun verrattiin Y402H genotyyppi ja alleelifrekvenssejä ruusu- tai tonsillitti 
potilasaineistojen (n=487) ja kontrolliaineiston välillä havaittiin, että Y402H 
polymorfia voi mahdollisesti liittyä alttiuteen sairastua näihin S. pyogenes 
bakteerin aiheuttamiin infektioihin. 
Tämä väitöskirjatutkimus osoittaa, että mikrobit voivat sitoa pinnalleen 
komplementin säätelijäproteiineja in vitro ja in vivo ja, että CFH:n sitominen on S. 
pyogenes bakteerille oleellista komplementtivälitteisen tuhoutumisen 
välttämiseksi. CFH:n Y402H polymorfiasta johtuvat vaihtelut CFH:n 
sitoutumisvoimakkuuksissa S. pyogenes bakteerin pinnalle vaikuttavat ratkaisevasti 
siihen, kuinka mikrobi pystyy välttämään komplementin tuhovaikutuksen ja tätä 
kautta selviämään veressä. Tämä selittää saadut tulokset CFH:n Y402H polymorfian 
assosioitumisesta tiettyihin S. pyogenes infektioihin. Koska CFH:n sitominen on S. 
pyogenes bakteerin virulenssille tärkeää, voidaan CFH:n sitoutumista estävää 
CFH5-7 fragmenttia kenties käyttää S. pyogenes infektioiden hoidossa.  
REVIEW OF LITERATURE 
The complement system 
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1 REVIEW OF LITERATURE 
 
With time the immune system has developed to an organized, powerful, and 
sensitive system that enables us to cope with foreign materials invading our body. 
Immunity is divided into two classes called acquired and innate immunity. 
Antibodies play a major role in the specific acquired immunity while activation of 
complement components occurs without previous antigenic stimulus. Complement 
system was described in 1889 when Hans Buchner demonstrated that a heat labile 
substance in blood serum was able to kill bacteria thus complementing the action 
of antibodies. Due to the “complementing” function, ten years later the system 
was named “complement” by Paul Ehrlich (Morgan, 1999). Within next 50 years it 
was generally belived that complement requires antibodies for activation. In 1954, 
however, Louis Pillemer demonstrated that the complement system can be 
activated independently from antibodies and by this way plays a central role in 
innate immunity (Pillemer et al., 1954). The evolutionary origin of the antibody-
independent complement activation system, later named the alternative pathway 
(AP), is much more ancient than that of the classical antibody-dependent system 
(classical pathway, CP). It is probable that components of AP first appeared to the 
superphylum Deuterostomia early in the evolutionary history. Within evolution 
several duplications in the complement genes took place and the innate immunity 
developed to a more complex system coincidentally with the adaptive immunity. 
In addition to the AP the third complement activation system, lectin pathway (LP), 
seems to have an ancient origin (Krushkal et al., 1998; Nonaka, 2001).  
 
1.1 The complement system 
 
Function of the complement system is based on recognition of targets leading to 
organized interactions between complement proteins that either promote or 
down regulate the cascade. The three activation cascades consist of several soluble 
proteins, and are regulated by at least five surface bound and 10 soluble 
regulators. In addition, there are surface bound receptors or proteins that, outside 
the complement system, mediate the complement-initiated immune response. 
The complement system has various roles in both innate and acquired immunity 
and also in cleaning immune complexes from body. These functions are mediated 
by the molecules generated during the activation cascades. Human deficiencies of 
complement components have emphasized the importance of the complement 
system in immunity (Figueroa and Densen, 1991).  
REVIEW OF LITERATURE 
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Defense against infections. The complement system acts directly on invading 
microbes by causing rapid destruction of some of the targets and generating 
covalently target-bound opsonizing molecules that enhance phagocytosis of the 
microbe by phagocytes. Also chemotactic factors and anaphylatoxins are 
generated at different stages of the activation cascades thus promoting the innate 
immune response.  
Function in clearance. Complement has an important role in removal of immune 
complexes and debris from the body. Circulating debris and immune complexes 
are attacked by the complement system followed by capture of the complexes by 
erythrocytes and transportation to be destroyed by macrophages in spleen or liver. 
Complement acts also in the clearance of necrotic and apoptotic cells (Gasque, 
2004). 
Linking the innate and adaptive immunity. Certain cleavage products of the 
complement activation cascades are recognized by specific complement receptors. 
Complement receptors expressed on lymphocytes have an important role in 
activation of these cells thus linking the innate and adaptive immunity (see chapter 
1.1.4).   1.1.1 Recognition 
 
In order to function properly the complement system must be activated through 
specific recognition, one of the key features of the innate immunity. The 
complement system has three strategies to distinguish self from nonself 
structures. These are recognition of “microbial nonself”, recognition of “missing 
self” and recognition of “altered self”(Medzhitov and Janeway, 2002).  
Microbial nonself. In general innate immunity can recognize certain conserved 
molecular patterns appearing commonly on micro-organisms. These are called 
pathogen associated molecular patterns (PAMPs) as reviewed here (Medzhitov 
and Janeway, 1997; Mogensen, 2009). Microbial nonself recognition by 
complement system is mediated via complement components such as C1q, 
mannan-binding lectin (MBL), and ficolins. C1q recognizes antigen-bound 
antibodies, MBL mannose and N-acetylglucosamine, and ficolins N-
acetylglucosamine residues on microbial surfaces (Matsushita and Fujita, 1992; 
Matsushita, 2009). 
Missing self. Self surfaces have membrane bound complement regulatory proteins 
that act as markers of normal self. During the last few years it has become more 
REVIEW OF LITERATURE 
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and more evident that also one plasma protein, factor H (CFH), that acts as a 
complement regulator of AP, has an important role in differentiating self cells from 
nonself cells. CFH recognizes the self cells partially by sialic acids and 
glycosaminoglycans on self surfaces (Fearon, 1978; Kazatchkine et al., 1979b; 
Pangburn, 2002; Kajander et al., 2011). Particles without these markers are missing 
self factors and are therefore immediately considered as targets for the 
complement attack.  
Altered self. Complement plays an important role in the safe disposal of apoptotic 
and necrotic cells. It has been suggested that complement mediated phagocytosis 
of apoptotic cells requires two signals. Nucleic acids exposed by apoptotic cells 
serve as self signals for complement component C1q while the loss of surface 
complement regulators act as missing self signals. This in turn induces complement 
activation and opsonization on the target leading to phagocytosis of the cell 
(Elward et al., 2005). Moreover, apoptotic cells acquire fluid phase complement 
regulators that protect the cells against excessive complement activation and 
inflammation (Trouw et al., 2007).  
 1.1.2 Activation 
 
When recognition of the target through the three basic signals, microbial nonself, 
missing self, or altered self, has occurred the complement can be activated. The 
activation is mediated through three pathways, CP, AP (Figure 1), and LP. When 
activated, all of these pathways generate an active enzyme, C5-convertase, that 
initiates the terminal pathway (TP) and formation of membrane attack complex 
(MAC).  
Classical pathway (CP). Activation of CP is initiated when C1q, a component of the 
C1-complex, recognizes its ligand attached to the target. The most well-known 
activating ligands of C1q are antigen-bound antibodies IgG1, IgG3 and polymerized 
IgM (Bindon et al., 1988; Collins et al., 2002). At least two IgG molecules are 
required for triggering the activation so that C1q is bound to the Fc parts of the 
antibodies (Hughes-Jones et al., 1984). This results in conformational change in C1-
complex (Brier et al., 2010) ensuring that a fluid phase antibody does not cause 
unnecessary complement activation. Molecules other than immunoglobulins, 
including lipid A region of bacterial lipopolysaccharide (Morrison and Kline, 1977) 
and components of damaged cells such as DNA, (Jiang et al., 1992a), C-reactive 
protein (CRP), (Jiang et al., 1992b) serum amyloid P component (SAP)(Ying et al., 
1993), and pentraxin 3 (PTX3) can activate the classical pathway in an antibody-
independent manner (Deban et al., 2010; Deban et al., 2011).  
REVIEW OF LITERATURE 
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  Figure 1. Classical and alternative pathways of complement activation. Complement proteins interact with each other in a sequence. When activated, both pathways lead to activation of the terminal pathway and formation of the membrane attack complex (MAC). The alternative pathway amplification loop is marked as a dashed curve. 
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The C1 complex is a large multimolecular complex (approximately 750 kDa) 
composed of a single C1q molecule, two molecules of C1r, and two molecules of 
C1s. C1s and C1r are linked noncovalently to the complex in a Ca2+ dependent 
manner (Lepow et al., 1963; Ziccardi and Cooper, 1977; Bally et al., 2009). They are 
both serine proteases having a molecular weight approximately 93 kDa (Sim et al., 
1977). C1q is composed of six identical subunits that are bound together 
noncovalently resembling a bunch of tulips. Each of these subunits can carry the 
antibody binding site within the globular head domain (Calcott and Müller-
Eberhard, 1972; Gadjeva et al., 2008). When C1-complex is bound to the 
antibodies the C1r subcomponents in the complex are autocatalytically activated 
thus activating the C1s subcomponents by cleavage (Naff and Ratnoff, 1968; Dodds 
et al., 1978; Budayova-Spano et al., 2002). Complement components C4 and C2 are 
both cleaved by C1s (Müller-Eberhard et al., 1967; Matsumoto et al., 1989).  
C4 is composed of three chains, α (93 kDa), β (78 kDa) and γ (44 kDa). These are 
linked together via three disulphide-bonds and noncovalent interactions. In fluid 
phase C4 is cleaved by C1s to C4b (198 kDa) and C4a (9 kDa) (Schreiber and Muller-
Eberhard, 1974). Upon activation C4b undergoes a conformational change 
exposing a thioester group that can form covalent amide- or ester bond with an 
amine or hydroxyl group nearby, presumably on the activation surface (Isenman 
and Kells, 1982; Dodds et al., 1996). Membrane-bound C4b then binds C2 in the 
presence of Mg2+ ions, exposing the C2 component for cleavage by C1s thus 
resulting in formation of a C4b2a complex, called CP C3-convertase (Müller-
Eberhard et al., 1967; Nagasawa and Stroud, 1977). The C3-convertase is an active 
enzyme where the C2a component promotes the CP activation by cleaving the 
central complement component, C3 (Cooper, 1975).  
The component C2 is an approximately 102 kDa single chain plasma protein and 
the two subunits cleaved by C1s have molecular weights 74 kDa (C2a) and 34 kDa 
(C2b) (Kerr and Porter, 1978). The role of C2b that is released upon activation of CP 
is not known but at least the C2b part has an important role in attachment of the 
intact C2 to C4b (Nagasawa and Stroud, 1977). The component C2 has an 
analogous function to factor B in AP (more detailed description in AP section) and 
these proteins also resemble each other in structure (Pryzdial and Isenman, 1987; 
Ponnuraj et al., 2004; Milder et al., 2006).  
Lectin pathway (LP). The first component of the LP was described when MBL, a 
serum lectin, was found to initiate the CP in an antibody independent way (Ikeda 
et al., 1987). MBL binds mannose and N-acetylglucosamine residues that are 
abundant in bacterial cell walls. The initiation of LP activation requires association 
of two C1r- and C1s-like mannose-associated serine proteases MASP-1 and MASP-
2 with MBL. Complement components C4 and C2 are both cleaved by MASP-2 
leading to propagation of the complement activation similarly to CP (Matsushita et 
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al., 1992; Sato et al., 1994; Thiel et al., 1997). It has also been shown that mouse 
MASP-1 and probably also MASP-3 both cleave and activate pro-factor D to factor 
D indicating their importance in AP activation (Takahashi et al., 2010). MBL and 
C1q are structurally related but, unlike C1q, MBL possesses sugar-binding lectin 
domains (Turner, 1996). In addition to MBL, LP can be activated by relatively 
recently described M-, L-, and H-ficolins or 1-, 2- and 3-ficolins, respectively. These 
all act as pattern recognition molecules that recognize carbohydrates on microbial 
surfaces such as N-acetylglucosamine. Similarly to MBL, ficolins are associated with 
MASPs at the early stage of complement activation cascade as reviewed recently 
(Matsushita, 2009).  
Alternative pathway (AP). C3 is the key component of all three pathways since all 
major effector functions of all complement pathways are mediated through 
activation of this molecule. It is a large 185 kDa molecule composed of two chains, 
α and β (Tack et al., 1979b). AP is activated spontaneously since C3 is continuously 
hydrolyzed at a low rate in human plasma to form a metastable C3(H20) (Pangburn 
et al., 1981). Within a short period of time (milliseconds) C3(H20) is able to bind 
factor B in a Mg2+-dependent manner exposing it to cleavage by factor D thus 
forming a C3(H20)Bb complex, the initial C3 convertase, in fluid phase. This 
complex cleaves fluid phase C3 to C3a and C3b and the freshly formed C3b can 
then attach onto any surfaces within a short time (Fearon and Austen, 1975a; 
Pangburn and Müller-Eberhard, 1980; Fishelson et al., 1984). The smaller cleavage 
fragment, C3a (9 kDa) of C3, is released and acts as an anaphylatoxin and 
chemotactic factor as reviewed earlier (Hugli, 1975). This spontaneous 
complement activation in fluid phase, characteristic only for AP, is constantly 
targeting all surfaces lacking sufficient down-regulators.  
Factor D is a 26 kDa serine protease. It can cleave the single chain factor B only 
when it is bound to C3(H2O) or C3b (Lesavre and Muller-Eberhard, 1978) since the 
conformational change in factor B during the complex formation, exposes factor B 
for activation by factor D (Janssen et al., 2009; Hourcade and Mitchell, 2011). 
When cleaved, Bb releases a fragment Ba (30 kDa) while Bb (60 kDa) acts as the 
serine protease in the formed C3-convertase, C3bBb (Medicus et al., 1976b; 
Lesavre et al., 1979).  
The cleaved C3b exposes a thioester group that can bind covalently to a target 
surface similarly to C4b in CP. At this stage the interaction between C3b and either 
factor B or CFH (see section 1.1.3.1) forms the molecular basis of the nonself vs. 
self discrimination of AP (Pangburn and Müller-Eberhard, 1978; Kazatchkine et al., 
1979a; Meri and Pangburn, 1990). Upon activation the C3 convertase, C3bBb, is 
formed similarly to the fluid phase C3(H20)Bb but unlike C3(H20)Bb the C3bBb 
complex can furthermore be stabilized by properdin (see section 1.1.3.1) (Medicus 
et al., 1976a). The amplification of AP occurs at this stage when C3 convertase 
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activates more fluid phase C3 by cleavage to C3b (Müller-Eberhard and Götze, 
1972). This amplification step causes effective C3b opsonization of the target (Shin 
et al., 1969).  
Terminal pathway (TP). Initiation of the TP and formation of MAC is caused by the 
surface bound C5 convertases (C4b2aC3b or C3bBbC3b) that cleave fluid phase C5 
(Muller-Eberhard, 1986). 
C5 is structurally related to C3 and C4 components consisting of two-chains, α 
(~140 kDa) and β (~80 kDa). These chains are linked together with disulphide 
bonds (Nilsson et al., 1975). C5 does not contain a thioester group that becomes 
exposed when C5 is converted to C5b. Therefore, C5b cannot bind covalently to 
surfaces (DiScipio, 1981). To get activated C5 can bind to surface-associated C5 
convertases (C4b2aC3b or C3bBbC3b) exposing itself for cleavage by C2a or Bb 
(Medicus et al., 1976b; Vogt et al., 1978). The C5a fragment cleaved from the α-
chain of C5 is an important anaphylatoxin while the C5b fragment remains 
attached to C3b in the complex (Tack et al., 1979a). The next two single chain 
proteins C6 (~104 kDa) and C7 (~92 kDa) bind to C5b in sequence (Discipio and 
Gagnon, 1982; DiScipio, 1992a) where the attachment of C7 to C6 causes a 
conformational change in the C5b67 complex releasing it from the convertase into 
the fluid phase. Within a short period of time the C5b67 complex is able to 
associate tightly into the target membrane (Podack et al., 1978a). Majority of the 
complexes do not reach the membrane in time and will be inactivated in fluid 
phase by S-protein (Podack et al., 1978b) or by C8 described next.  
Component C8 is a molecule having similarities with C6 and C7. It is composed of 
three chains, α (64 kDa), β (64 kDa), and γ (22 kDa). The subunit α is disulphide 
bonded to γ while this dimer is then noncovalently associated with β. C8 α subunit 
of C8 is the first complement protein penetrating the cell membrane (Steckel et al., 
1980; Hadders et al., 2007). C8 has a dual role in the complement cascade, 
inhibitory and promoting. Binding of C8 to C5b67 in fluid phase limits attachment 
of the complex into the membrane while being required for the MAC formation on 
the surface (Nemerow et al., 1979). Binding of C8 to the surface-attached C5b67 
attaches the complex more deeply into the membrane and enables binding of the 
last complement component, C9, to C8 (Kolb and Müller-Eberhard, 1974). C9 is a 
single chain protein (69 kDa) homologous with C6, C7, and C8. While attached to 
C8 C9 is unfolded exposing binding sites for additional C9 components (up to 12-16 
molecules) that together form a transmembrane pore (Podack et al., 1982).  
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1.1.3 Regulation 
 
In the activation cascade C3b must reach the target within a short period of time 
to avoid hydrolysis and rapid degradation. Furthermore, the formed C3 
convertases decay rapidly in the absence of properdin. In the TP the C5b-7 
complexes that do not attach to a surface bind C8 in the fluid phase and thereby 
become inactivated. However, this non-specific regulation is not sufficient to 
control complement activation because of the efficient amplification steps of the 
system. Upon activation the complement system has a tendency to propagate in 
an explosive manner. Especially the low grade constant activation of AP in plasma 
can lead to amplification very easily and become harmful even for the host as 
exemplified by several disease processes (see section 1.1.3.1). Without specific 
regulation (Figure 2) complement activation would also consume the components 
that are needed for activation leading to acquired (secondary) complement 
deficiency and thereby complement inactivity.  
Genes coding several regulators of complement activation (RCA) are located in 
chromosome 1q32 within a 900 kb segment called RCA gene cluster (Lublin et al., 
1987). These regulators are C4b-binding protein (C4BP), complement receptor 1 
(CR1) (Rodriguez de Cordoba et al., 1984), CFH/factor H-like protein 1 (CFHL-1) 
(Rodriguez de Cordoba et al., 1985), decay accelerating factor (DAF) (Lublin et al., 
1987) and membrane cofactor protein (MCP) (Lublin et al., 1988) presented in the 
order of description. CR1, DAF and MCP are membrane-associated regulators while 
CFH, CFHL-1, and C4BP are fluid-phase regulators. In addition to their close 
location in genome these proteins share similarities in their structure and function. 
They all contain four or more short consensus repeat domains (SCR or complement 
control protein module, CCP) that are arranged in row resembling “beads on a 
string”. Each SCR is a globular domain containing approximately 60 amino acids. 
The bead-like conformation is maintained by four cystein residues that form a 
triple loop structure via two intradomain disulphide bonds that are always linked 
in a 1-3, 2-4 pattern (Klickstein et al., 1987).  
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 Figure 2. Classical and alternative pathways of complement activation are regulated by soluble and surface bound regulators (marked in italics). Carboxypeptidase N (CPN) acts on C3a and C5a formed by both pathways. The alternative pathway amplification loop is marked as a dashed curve.  
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1.1.3.1 Soluble complement regulators 
C1-inhibitor (C1inh). Upon activation of CP cross-linking of the globular head 
domains of C1q results in a conformational change in this molecule (Vandenberg 
and Easterbrook-Smith, 1986) causing autoactivation of C1r and further activation 
of the serine protease C1s by C1r as explained above. At this stage C1inh is able to 
regulate the activation by binding to C1r and C1s causing their dissociation from 
C1q. C1inh also regulates CP activation in fluid phase by acting on C1 that 
otherwise could be spontaneously autoactivated by non-immune activators at low 
levels (Ziccardi, 1982). C1inh has an important role in inhibiting various other 
proteases outside the complement system such as factors in the blood coagulation 
cascade and kinin-kallikrein system (Schapira et al., 1983; Wuillemin et al., 1995). 
C1inh is a serine protease inhibitor (serpin) and is consumed by the interaction 
with the target protease. It is a heavily glycosylated single chain protein with a size 
of 105 kDa (Harrison, 1983). It has a two-domain structure with the reactive serpin 
domain in the globular carboxyl-terminus and the glycosylated domain in the tail-
like amino-terminus (Odermatt et al., 1981; Bock et al., 1986; Davis et al., 1986). It 
is the only inhibitor of C1q and a deficiency in C1inh results in hereditary 
angioedema (HAE), a disease characterized by recurrent acute edema of skin or 
mucosa. The symptoms in this disease  are mainly or totally due to the lack of 
regulation of kallikrein by C1inh and the generation of the potent vasoactive 
peptide bradykinin in patient plasma (Pappalardo et al., 2002). 
C4b-binding protein (C4BP). After initiation of CP by C1 the next step which is 
regulated specifically is the C4b stage. This is performed by C4BP that interferes 
with the assembly of surface bound CP C3-convertase C4b2a by accelerating its 
natural decay. It also acts as a cofactor for factor I in cleavage of both surface 
bound and fluid phase C4b to C4c and C4d (Gigli et al., 1979). 
C4BP is encoded by a gene in the RCA gene cluster and is mainly expressed in the 
liver. It is a 540-590 kDa protein consisting of several disulphide bonded subunits 
(Scharfstein et al., 1978) forming together a spider-like structure (Figure 3) 
(Dahlbäck et al., 1983) and the most common isoform has seven identical α-chains 
(70 kDa each) and one β-chain (45 kDa) (Sanchez-Corral et al., 1995). The α-chain is 
composed of eight SCR-domains (Chung et al., 1985) and the β-chain from three 
(Hillarp and Dahlbäck, 1990). The chains are carboxyl-terminally linked to a central 
“core” of the spider-like molecule. The most amino-terminal domains 1 and 2 of 
the α-chain are likely required for C4b binding and cofactor activities (Blom et al., 
2000b) while the β-subunit is required for binding to protein S (Hillarp and 
Dahlbäck, 1988) probably via domains 1 and 2 (van de Poel et al., 1999a; van de 
Poel et al., 1999b). Protein S is a vitamin K-dependent molecule of coagulation 
cascade and its role in the C4BP-protein S -complex is unclear. However, when 
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bound to C4BP, coagulation-associated functions of protein S remain inactive and 
it does not affect the regulatory functions of C4BP (Dahlbäck, 1986).  
 
 Figure 3. C4BP has a spider-like structure. The seven identical α-chains contain eight domains and the cofactor activity site is located within domains 1 and 2. The β-chain has three domains and binds protein S. Figure modified from Sanchez-Corral et al. 1995 (Sanchez-Corral et al., 1995). 
 
Factor H (CFH). AP can be initiated on any surface where C3b becomes deposited. 
Whether AP is activated or not is believed to depend on the relative abundance of 
polyanions on the cell surface, such as glycosaminoglycans or sialic acids. These 
anionic structures favor binding of CFH rather than factor B to surface bound C3b 
leading to down-regulation of AP. When bound on the surface CFH regulates AP 
indirectly by acting as a cofactor for the inactivation of C3b by factor I (Pangburn et 
al., 1977). It also directly inhibits the formation of C3-convertases by interfering 
with the binding of factor B to C3b (Pangburn and Müller-Eberhard, 1978) and 
furthermore increases the pace of the natural decay of already formed AP 
convertases (Weiler et al., 1976; Whaley and Ruddy, 1976).  
REVIEW OF LITERATURE 
The complement system 
 
25 
 
CFH is an elongated, approximately 155 kDa single-chain glycoprotein (Sim and 
DiScipio, 1982) consisting of 20 SCR domains (Ripoche et al., 1988) (Figure 4). The 
cofactor and decay acceleration activities of CFH are located within the first four 
amino-terminal domains (Gordon et al., 1995; Kühn et al., 1995; Kühn et al., 1996) 
while the main surface recognition site is within domains 19-20 (Pangburn, 2002; 
Jokiranta et al., 2005; Ferreira et al., 2006). CFH interacts with C3b via both 
domains 1-4 and 19-20 while an additional, probably less important, C3b 
interaction sites are found within domains 8-18 (Jokiranta et al., 1996; Sharma and 
Pangburn, 1996; Jokiranta et al., 2000; Jokiranta et al., 2005; Wu et al., 2009). The 
dual interaction of CFH via domains 19-20 with C3b and nonactivator surface 
glycosaminoglycans or sialic acids explains the molecular basis between self and 
nonself discrimination by CFH (Kajander et al., 2011). CFH interacts with heparin 
via domains seven (Blackmore et al., 1996; Sharma and Pangburn, 1996) and 20 
(Blackmore et al., 1998b), and possibly weakly through domain 9 (Ormsby et al., 
2006). In addition, it has been suggested, although not confirmed, that CFH binds 
polyanions/sialic acids via domains 13 (Pangburn et al., 1991). Moreover, CFH 
interacts with neisserial sialic acids via domains 16-20 (Ram et al., 1998b).  
 
 Figure 4. CFH has a elongated structure with 20 domains. The major C3b-binding sites (marked with grey color) are located in domains 19-20 and 1-4 where the latter is the cofactor activity site. CFH polymorphism Y402H is located within domain seven (marked with stripes). CFH is presented as a flexible molecule according to electron microscopy studies (DiScipio, 1992b). 
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Several mutations in CFH have been reported in renal diseases. Those located in 
the carboxyl-terminus are associated with atypical hemolytic-uremic syndrome 
(aHUS) (Warwicker et al., 1998; Richards et al., 2001) while at least one mutation 
in the amino-terminus is associated with dense deposit disease (DDD), earlier 
called membranoproliferative glomerulonephritis type II (MPGN) (Licht et al., 
2006). In addition to mutations, a large number of CFH polymorphisms have been 
identified (Rodriguez de Cordoba et al., 2004). Some polymorphisms have been 
found to be associated with aHUS (Caprioli et al., 2003) while one polymorphism in 
the domain seven is strongly associated with AMD, the most common cause of 
visual loss of the elderly in industrialized countries (Edwards et al., 2005; Hageman 
et al., 2005; Haines et al., 2005; Klein et al., 2005). The Y402H polymorphism is 
located in domain seven close to or within the sites that have been shown to bind 
heparin, CRP, and Streptococcus pyogenes M protein (Giannakis et al., 2003). 
Further studies have shown that the CFH(402H) allotype shows impaired binding to 
CRP partially explaining the inflammation in macula of individuals with AMD (Laine 
et al., 2007). The Y402H polymorphism has also been shown to affect CFH binding 
to heparin (Clark et al., 2006) and a crystal structure of the CFH6-8 region 
containing the polymorphic amino acid suggests that the 402Y residue is directly 
involved in binding of CFH on surface glycosaminoglycans (Prosser et al., 2007). 
Additionally the Y402H polymorphism affects CFH binding to necrotic cells (Sjöberg 
et al., 2007) indicating that the alteration of CFH interaction with these structures 
could potentially lead to increased or reduced complement activation at the 
location and thereby affect the disease progression. However, it is still unclear why 
these polymorphisms have been enriched in the human population despite of their 
association with harmful diseases. 
Factor H-like protein 1 (CFHL-1). CFHL-1 is encoded by the same gene as CFH by 
alternative splicing. It is a 45-50 kDa protein consisting of the first seven amino-
terminal domains of CFH followed by four additional amino acids (Ripoche et al., 
1988). Similarly to CFH, CFHL-1 has cofactor and decay accelerating activities 
within domains 1-4 (Kühn et al., 1995; Kühn et al., 1996) but it lacks the surface 
recognition capacity of full length CFH. 
Complement factor H-related proteins 1-5 (CFHR-1, CFHR-2, CFHR-3, CFHR-4A , 
CFHR-4B, CFHR-5). There are six complement CFH-related proteins (CFHR) that 
share structural similarities with CFH and are also encoded by genes in the RCA 
gene cluster. CFHR-1 is composed of five SCR domains and can be found in two 
different glycosylated forms in plasma, CFHR-1α (37 kDa) and CFHR-1β (42 kDa) 
(Timmann et al., 1991). Regulatory function for CFHR-1 has been suggested. It 
probably acts on the TP by binding C5 and C5b6 thus inhibiting the cleavage of C5 
and formation of C5b67 complex (Heinen et al., 2009). CFHR-2 consists of four SCR 
domains (Skerka et al., 1992) while both CFHR-3 and CFHR-4B have five SCR 
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domains and CFHR-4A and CFHR-5 have nine (Skerka et al., 1997; McRae et al., 
2001; Jozsi et al., 2005). At least CFHR-5 has weak cofactor activity for factor I 
(McRae et al., 2005). CFHR-3 and CFHR-4B both interact with the C3d region of C3b 
similarly to CFH indicating that they also might have regulatory activity which, 
however, has not been shown (Hellwage et al., 1999). 
Properdin. Stabilization of the formed C3/C5 convertases of the AP is mediated by 
properdin making it the only positive regulator of complement activation. 
Stabilizing the convertases decreases the rate of their natural decay (Fearon and 
Austen, 1975b; Medicus et al., 1976a). According to the early suggestion of Louis 
Pillemer (Pillemer et al., 1954) properdin can probably also initiate AP activation. 
Recent studies have shown that it directly (in the absence of C3b) binds on 
surfaces of Neisseria gonorrhoeae (Spitzer et al., 2007) and Chlamydia pneumoniae 
(Cortes et al., 2011) indicating its role as a pattern recognition molecule. The gene 
encoding properdin is located in X-chromosome (Goundis et al., 1989). Properdin 
exists in plasma as oligomers of two to four monomers linked together in a cyclic 
fashion (Figure 5) (Smith et al., 1984). Each 52 kDa monomer consists of six 
thrombospondin repeat-domains with conserved residues that are also found in 
thrombospondin and complement components C6, C7, C8, and C9 (Nolan et al., 
1991). 
 
 Figure 5. Properdin oligomers. Each properdin monomer has six thrombospondin repeat-domains. The monomers are arranged as cyclic dimers, trimers and tetramers. Figure modified from (Smith et al., 1984). 
 
S-protein (vitronectin). S-protein regulates the complement activation by binding 
fluid phase C5b-7 thereby preventing the association of the unstable hydrophobic 
membrane-binding site of the complex onto the membrane. It has also been 
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suggested that S-protein interferes with C9 polymerization within the membrane-
associated C5b-9 complex (Podack et al., 1984). The name vitronectin comes from 
its property to mediate cell attachment to tissues similarly to fibronectin (Hayman 
et al., 1983). The name S-protein (S for site specific) comes from the observation 
that it regulates the C system competing for the membrane-binding sites with 
terminal activation complexes (Podack et al., 1978b). S-protein also binds heparin 
suggesting that it interferes with the anticoagulation system (Preissner and Muller-
Berghaus, 1987). In plasma, S-protein exists at least in two forms, a single chain 
molecule (84 kDa) and a two chain molecule where the subunits (69 kDa and 15 
kDa) are linked together with disulfide bonds. It probably also forms dimers and 
higher molecular weight aggregates in plasma (Podack and Muller-Eberhard, 
1979).  
Clusterin (SP-40,40). Similarly to S-protein clusterin binds fluid phase C5b-7 
making it incapable to associate with membranes (Murphy et al., 1989). Of the 
isolated late complement components, clusterin associates with C7, C8, and C9. 
The binding of C9 to clusterin suggests that, in addition to membrane association, 
clusterin also inhibits the C9-polymerization and thereby formation of the 
transmembrane pore (Tschopp et al., 1993). The name clusterin comes from the 
property of the protein to stimulate cell adhesion and aggregation (Blaschuk et al., 
1983). It is a heterodimeric serum glycoprotein composed of α- and β-chains both 
having a molecular weight of approximately 40 kDa. The heavily glycosylated 
chains are linked together by disulphide bonds (Murphy et al., 1988). 
Factor I (C3b inactivator). Factor I regulates the complement system by 
inactivating C4b and C3b molecules generated upon activation. However, factor I 
cannot function without a cofactor. In the presence of a cofactor, either C4BP 
(Fujita et al., 1978), CR1 (Iida and Nussenzweig, 1981), or MCP (Seya et al., 1986), 
factor I cleaves the α-chain of C4b at two sites leaving the surface bound C4d (47 
kDa α2 chain) attached on the membrane and releasing the large C4c (consisting of 
chains α3, α4, β, and γ) fragment in the fluid phase.  
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Figure 6. Inactivation of C3b by factor I and the cofactors. The α-chain is cleaved by factor I in two steps. In the first step two first cleavages require the cofactor activities of CFH, MCP or CR1 while in the second only CR1 can act as a cofactor.  
Unlike the cleavage of C4b the cleavage of C3b by factor I occurs in two steps. The 
first two cleavages of C3b splits the α´-chain into two fragments (68 kDa and 43 
kDa) giving rise to an inactive iC3b molecule while releasing a small C3f fragment 
(Figure 6) (Harrison and Lachmann, 1980). The generated iC3b does not bind factor 
B and therefore cannot promote further AP activation (Ross et al., 1983). The first 
two cleavages requires the presence of cofactors CFH (Pangburn et al., 1977), MCP 
(Seya et al., 1986) or CR1 (Fearon, 1979). Factor I can further cleave the iC3b 
molecule releasing C3c in the fluid phase and leaving the C3dg attached on the 
membrane. Only CR1 has cofactor activity for this third cleavage under 
physiological conditions (Ross et al., 1982). C3b and its cleavage fragments iC3b 
are both opsonic fragments. Therefore the cleavage of iC3b to C3dg by CR1 on host 
cell surfaces is crucial for protection against phagocytosis (van Lookeren Campagne 
et al., 2007). 
Factor I is approximately a 90 kDa enzyme consisting of a heavy (50 kDa) and a 
light chain (38 kDa) linked together by a disulphide bond. The serine protease 
activity is located in the light domain while the C3b-binding site is in the heavy 
domain (Goldberger et al., 1987; DiScipio, 1992b; Roversi et al., 2011).  
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Carboxypeptidase N (CPN). When activated, the complement proteases cleave 
components C3, C4 and C5 releasing small polypeptides to the fluid phase. The 
released C5a and C3a are both powerful anaphylatoxins that trigger the 
inflammatory response, C5a being clearly more efficient. Although these 
polypeptides share similarities in structure and function, only C5a is able to 
promote chemotaxis (Fernandez and Hugli, 1978). To inhibit an excessive 
inflammatory response, these mediators are quickly and efficiently inactivated by 
an anaphylatoxin inactivator, CPN, that removes an arginine residue from the 
mediators thus forming the molecules C5aDes-Arg or C3aDes-Arg (Bokisch and 
Müller-Eberhard, 1970). These DesArg forms have reduced or no anaphylatoxic or 
chemotaxic activity because of reduced binding to C3aR or C5aR (see section 
1.1.4).  
 
1.1.3.2 Membrane associated regulators 
Complement receptor 1 (CR1, CD35). This 205 kDa molecule was first isolated 
from erythrocyte membranes. It has an important role in complement regulation 
on cell surfaces and in the clearance of fluid phase immunocomplexes. In addition 
to the cofactor activities in cleavage of C4b and C3b (see above) it also has decay 
accelerating activity on the convertases C3bBb (Fearon, 1979), C4b2a and 
C4b2aC3b (Iida and Nussenzweig, 1981). Processing of immune complexes by CR1 
is a dynamic event where both CR1 mediated cofactor activity and ligand 
recruitment plays an important role. CR1 is a receptor for C3 and C4 cleavage 
fragments C3b, iC3b and C4b (Ross et al., 1983). It effectively attracts C3b 
opsonized fluid phase immune complexes to the surface of erythrocytes but easily 
releases them when C3b is inactivated to iC3b by factor I. Thereby the CR1 
molecule becomes unoccupied and can rapidly rebind to adjacent C3b molecule 
causing a dynamic “binding and release” event (Medof et al., 1982a; Medof et al., 
1982b; Medof et al., 1982c). As a result the opsonized immune complexes are 
easily delivered to tissue macrophages for phagocytosis. CR1 is also a cellular 
receptor for C1q (Klickstein et al., 1997) and MBL (Ghiran et al., 2000).  
The gene for CR1 is located in the RCA gene cluster. CR1 is a polymorphic 
membrane associated protein where the most common form, type F (Wong et al., 
1983), is composed of four repeating units (long homologous repeats, LHR) 
consisting of seven SCRs each, two additional carboxyl-terminal SCRs (total of 30 
SCRs) followed by transmembrane and cytoplasmic regions (Figure 7) (Klickstein et 
al., 1987). CR1 has distinct binding sites for C3b and C4b. The two amino-terminal 
SCRs in LHR-A bind C4b while the two amino-terminal domains in LHR-B and LHR-C 
bind C3b (Klickstein et al., 1988). 
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Complement receptor of the Immunoglobulin family (CRIg). CRIg is a complement 
receptor expressed on tissue macrophages. It mediates opsonophagocytosis by 
binding C3b and iC3b on opsonized particles (Helmy et al., 2006). When bound to 
C3b CRIg regulates AP activation by inhibiting the interaction of C3 and C5 with AP 
convertases (Wiesmann et al., 2006).  
Decay accelerating factor (DAF or CD55). As the name indicates DAF is able to 
regulate the AP and CP by accelerating the decay of C3-convertases. It associates 
with C4b and C3b on the membrane and dissociates Bb and C2a from the 
convertases (Fujita et al., 1987). Unlike CFH, C4b, MCP, and CR1 it has no cofactor 
activity. DAF is a 70 kDa membrane protein composed of four SCR domains and a 
“spacer” serine/threonine/proline (STP)-rich region (Figure 7). It is anchored on the 
cell membrane via a glycosylphosphatidylinositol (GPI) anchor (Medof et al., 1987). 
For the decay accelerating function on C4b2a the domains SCR2-3 are essential 
while in the case of C3bBb the domains SCR2-4 are needed (Brodbeck et al., 1996). 
Also the STP region is essential for regulation in both pathways (Coyne et al., 
1992). 
Membrane cofactor protein (MCP or CD46). MCP was originally named gp45-70. 
This 50-85 kDa heavily glycosylated membrane protein has cofactor activity for the 
cleavages of C4b and the first cleavage of C3b by factor I but has no decay 
accelerating activity on the C3-convertases (Seya et al., 1986). MCP is widely 
expressed on cells but absent from human erythrocytes (Seya et al., 1988). MCP 
has structural similarity with DAF having four SCR domains and a heavily 
glycosylated STP region but unlike DAF, MCP has transmembrane and cytoplasmic 
domains (Figure 7) (Lublin et al., 1988). Alternative splicing of the gene encoding 
MCP results in isoforms that differ from each other in the composition of STP and 
cytoplasmic tail regions. Several isoforms can be expressed in the same cell (Post 
et al., 1991). SCR domains 2-4 of MCP are important for the regulatory activity 
while the domains 3 and 4 are essential for both ligand binding and cofactor 
activity (Adams et al., 1991). 
CD59 (protectin). At the final step of TP, multiple C9 molecules incorporate into 
the target membrane forming a channel that causes cell lysis. CD59 binds tightly to 
the membrane associated C5b-8 complex preventing the unfolding of C9 (Meri et 
al., 1990) and thereby C9-incorporation to the membrane (Rollins and Sims, 1990). 
CD59 is widely and abundantly expressed by blood cells and several other cell 
types (Meri et al., 1991). This 18-20 kDa single chain protein has five intra-chain 
disulphide bonds, it is heavily glycosylated and has a GPI anchor (Davies et al., 
1989; Sugita et al., 1993; Jokiranta et al., 1995). 
 
REVIEW OF LITERATURE 
The complement system 
 
32 
 
 Figure 7. Cell surface regulators DAF, MCP, and CR1. DAF and MCP are composed of four SCR domains and a glycosylated STP rich spacer between the domains and the membrane. CR1 is composed of repeating seven domain units and transmembrane and cytoplasmic regions. Also MCP is anchored on the cell membrane via a transmembrane domain while DAF has a GPI anchor.  1.1.4 Complement receptors 
 
The function of most complement receptors is to mediate a signal for activation of 
the cell upon binding to a complement cleavage product. Two receptors, CR1 and 
CRIg (described above), have also complement regulatory activity. 
Complement receptor 2 (CR2, CD21). CR2 has an important role in linking innate 
and adaptive immunity by mediating activation of B-cells. Cleavage of C3b to iC3b 
and further to C3dg by factor I exposes a CR2-binding site on the components 
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(Ross et al., 1983; van den Elsen and Isenman, 2011). The role of CR2 in B-cell 
activation is based on covalent attachment of C3dg to an antigen recognized by B-
cell receptor (surface immunoglobulin, sIgM). Crosslinking of sIgM and the B-cell 
surface complex consisting of CR2, CD19 and CD81 (TAPA-1) significantly lowers 
the threshold required for B-cell activation as reviewed earlier (Carter et al., 1988; 
Fearon and Carter, 1995).  
C3d, or actually C3dg, has been shown to act as molecular adjuvant in vivo in a 
mouse model increasing the immunogenicity of the antigen 1000 to 10,000 fold 
(Dempsey et al., 1996). The gene encoding CR2 is located in RCA gene cluster (Weis 
et al., 1987) and the expressed protein is composed of 15 or 16 SCR domains, a 
transmembrane domain, and a cytoplasmic tail (Weis et al., 1988). CR2 is 
sometimes referred as EBV receptor because Epstein -Barr virus uses it for entry 
into host B-cells (Fingeroth et al., 1984).  
Complement receptor 3 and 4 (CR3, CD11b/CD18 and CR4, CD11c/CD18). The 
integrin receptors CR3 and CR4 are both transmembrane heterodimers and 
expressed on monocytes, macrophages, neutrophils and lymphocytes as reviewed 
recently (van Lookeren Campagne et al., 2007). The C3b-derived cleavage product 
iC3b is a ligand for both CR3 (Ross et al., 1983) and CR4 (Micklem and Sim, 1985). 
These interactions enhance phagocytosis of the target by monocytes and 
macrophages (Myones et al., 1988).  
C3a receptor, C5a receptor, and C5a-like receptor (C3aR, C5aR and C5L2). C3a, 
C5a, and to lesser extent C5aDesArg, are pro-inflammatory polypeptides 
generated after the proteolytic cleavage of C3 and C5. These are then captured by 
specific receptors C3aR, C5aR, and C5L2 on various surfaces causing activation of 
cells carrying these receptors. These receptors share high sequence homology (Lee 
et al., 2001) but differ in ligand specificity and function. C3aR is the receptor for 
C3a but cannot recognize and be activated by C3aDesArg or C5a (Wilken et al., 
1999). C5aR binds C5a and more weakly C5aDesArg while C5L2 has equal or even 
higher affinity for C5aDesArg compared to C5a. Therefore, it has been suggested 
that, while C5aR has a pro-inflammatory role, C5LR is controlling both pro-
inflammatory and regulatory responses (Gerard et al., 1989; Cain and Monk, 2002; 
Okinaga et al., 2003; Chen et al., 2007; Scola et al., 2007). Anaphylatoxins C3a and 
C5a can also interact with C3aR and C5aR on T-cells and by this way participate in 
T-cell activation and thereby in adaptive immunity responses (Strainic et al., 2008). 
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1.2 Microbes and complement resistance 
 
An invading microbe is a definite target for the innate immune system and will be 
rapidly eliminated if the microbe does not possess any immune evasion 
mechanisms. Some decades ago it was noticed that complement, in the absence of 
antibodies, can be efficient enough to kill gram-negative bacteria by direct lysis 
(Schreiber et al., 1979) or gram-positive bacteria via complement-mediated 
opsonophagocytosis (Li and Mudd, 1965). Since complement forms one of the 
major innate immune defense mechanisms against bacterial pathogens, 
emergence of virulence factors that specifically inhibit complement have been 
favored by natural selection. Over the last two decades it has become clear that 
there are several microbial complement evasion strategies that practically cover 
each single complement activation step. Several examples show that one microbe 
can have multiple complement evasion strategies and these in combination 
contribute to complement resistance.  
Interference with complement activation by microbial components. Certain 
microbial structures such as the capsule of Escherichia coli or Staphylococcus 
aureus cannot activate AP in the absence of anti-capsular antibodies (Verbrugh et 
al., 1982; Bortolussi et al., 1983). Even when antibodies are present S. aureus, for 
example, uses protein A for antimicrobial IgG Fc binding and consequently 
interferes with IgG opsonization and CP activation (Forsgren and Sjöquist, 1966; 
Sjöquist and Stålenheim, 1969). Some microbes expose structures similar to 
complement regulatory proteins and use these to interfere with complement 
activation. For example Vaccinia virus expresses a secretory protein, Vaccinia virus 
complement-binding protein (VCP), that is structurally related to C4BP (Kotwal and 
Moss, 1988). Trypanosoma cruzi trypomastigotes (Joiner et al., 1988) and the 
herpes simplex virus 1 (HSV-1) (Fries et al., 1986) both express a protein with 
decay accelerating activity on C3bBb. In addition, proteins produced by S. aureus 
have been shown to interfere with formation or function of C3- and/or C5-
convertases and thereby C3b deposition, C5a formation and phagocytosis 
(Rooijakkers et al., 2005; Bestebroer et al., 2010; Jongerius et al., 2010).   
Degradation of complement components. Several pathogenic microbes have been 
shown to secrete enzymes that degrade complement components. C3 is the key 
component of all activation pathways and for this reason probably the main target 
for complement component cleaving microbial enzymes. For example, S. pyogenes 
protease SpeB (Terao et al., 2008), certain Pseudomonas aeruginosa enzymes 
(Hong and Ghebrehiwet, 1992; Schmidtchen et al., 2003), and S. aureus aureolysin 
(Laarman et al., 2011) attack C3 while a enterohemorrhagic E. coli serine protease 
EspP degrade both C3 and C5 (Orth et al., 2010) and a surface protease PgtE of 
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Salmonella enterica cleaves C3b, C4b and C5 (Ramu et al., 2007). Moreover, 
enzymes expressed by Aspergillus fumigatus (Behnsen et al., 2010) and Candida 
albicans (Gropp et al., 2009) have been shown to act on C3 and on intact or 
cleaved C4 thus causing non-specific degradation of complement components.  
The C5a anaphylatoxin and chemotactic factor is the key component enhancing 
inflammation and chemotaxis towards the invading microbe. Streptococcal 
bacteria, S. pyogenes (Wexler et al., 1985) and Streptococcus agalactiae (Bohnsack 
et al., 1991), both produce C5a-cleaving enzymes. Whether these enzymes also 
cleave C3a, like a proteinase produced by the protozoa Entamoeba histolytica 
(Reed et al., 1995), is not yet known. 
 1.2.1 Binding of host complement regulators  
 
Another way to regulate complement activation on microbial surface is the 
acquisition of host complement regulators. The usage of complement regulatory 
proteins in immune evasion by several pathogenic microbes is summarized in 
Tables 1 and 2.  
 1.2.1.1. Binding of C4BP 
Binding of C4BP to C4b down regulates both CP and LP. Several microbes have 
been shown to use specific ligands for C4BP binding. The studies on the 
interactions between C4BP and microbial ligands have shown that binding is 
mediated via the domains within the α-chain of C4BP. From these E. coli K1 OmpA 
binds to domain 3 of the α-chain, (Prasadarao et al., 2002) and Neisseria 
gonorrhoeae porin Por1A to domain 1 (Ram et al., 2001b). Domains two, five, and 
seven are needed for full binding of Moraxella catarrhalis UspA (Nordström et al., 
2004). For binding of C4BP to Neisseria meningitidis PorA, domains 2 and 3 (Jarva 
et al., 2005) and for yeast C. albicans Pra1, domains four, seven, and eight of the α-
chain are needed (Luo et al., 2011). Host C4BP is also bound by YadA and Ail of 
Yersinia enterocolitica (Kirjavainen et al., 2008), Bordetella pertussis FHA (Berggård 
et al., 1997) and Borrelia recurrentis CihC (Grosskinsky et al., 2010) but the 
interacting domains are not yet known. In addition, several S. pyogenes serotypes 
have been shown to bind C4BP (Thern et al., 1995) where the specific binding sites 
of M4 and M22 proteins have been shown to overlap with the C4b-binding site in 
domains 1-2 of the C4BP α-chain (Accardo et al., 1996; Blom et al., 2000a).  
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Table 1. Microbial acquisition of host complement regulatory proteins C4BP and CFH 
Protein Microbe Ligand Reference 
C4BP Bordetella pertussis FHA (Berggård et al., 1997) 
 Borrelia burgdorferi s.l. 
 
? (Pietikäinen et al., 2010) 
 Borrelia recurrentis CihC (Grosskinsky et al., 2010) 
 Candida albicans Pra1 (Luo et al., 2011) 
 Escherichia coli OmpA (Prasadarao et al., 2002) 
 Moraxella catarrhalis UspA (Nordström et al., 2004) 
 Neisseria gonorrhoeae Por1A (Ram et al., 2001b) 
 Neisseria meningitidis PorA (Jarva et al., 2005) 
 Salmonella enterica Rck (Ho et al., 2011) 
 Streptococcus pyogenes M protein (Thern et al., 1995) 
 Yersinia enterocolitica YadA, Ail (Kirjavainen et al., 2008) 
CFH 
 
Aspergillus fumigatus*#  ?  (Behnsen et al., 2008) 
 Bordetella parapertussis  ? (Amdahl et al., 2011) 
 Bordetella pertussis  ? (Amdahl et al., 2011) 
 Borrelia burgdorferi s.l. 
 
BbCRASP* (Kraiczy et al., 2001; Hartmann et al., 2006) 
 OspE 
 
(Hellwage et al., 2001) 
 Borrelia hermsii FhbA (Hovis et al., 2006) 
 Candida albicans Gpm1p*  (Poltermann et al., 2007) 
  Pra1* (Luo et al., 2009) 
 Fusobacterium necrophorum  ? (Friberg et al., 2008) 
 Haemophilus influenzae  ? (Hallström et al., 2008) 
 Leptospira interrogans LfhA (Verma et al., 2006) 
 Neisseria gonorrhoeae Por1A*,#  (Ram et al., 1998a) 
  Por1B*,# (Ngampasutadol et al., 2008) 
 Neisseria meningitidis Fhbp (Schneider et al., 2009) 
  NspA (Lewis et al., 2010) 
 Onchocerca volvulus  ? (Meri et al., 2002) 
 Pseudomonas aeruginosa Tuf# (Kunert et al., 2007) 
 Salmonella enterica Rck (Ho et al., 2010) 
 Streptococcus agalactiae β protein, (Areschoug et al., 2002) 
  SHT (Maruvada et al., 2009) 
 Streptococcus pneumoniae Hic (Jarva et al., 2004) 
  PspC  (Hammerschmidt et al., 2007) 
 Streptococcus pyogenes 
 
 
 
Fba* (Pandiripally et al., 2002) 
 M protein*  
 
(Horstmann et al., 1988) 
  Scl# (Reuter et al., 2010) 
 Yersinia enterocolitica Ail (Biedzka-Sarek et al., 2008) 
  YadA (China et al., 1993) 
*Binds also CFHL-1, # Binds also CFHR-1 
Abbreviations: Ail¸ attachment-invasion locus protein; CihC, complement inhibition via C4bp; BbCRASP, Borrelia burgdorferi 
complement regulator-acquiring surface proteins; Fba, fibronectin-binding protein; FHA, filamentous hemagglutinin; FhbA, factor 
H-binding protein; Fhbp, factor H-binding protein; Gpm, phosphoglycerate mutase: Hic, factor H-binding inhibitor of complement; 
LfhA, Leptospira factor H-binding protein; Nsp, neisserial surface protein; Omp, outer membrane protein; Osp, outer surface 
protein; Por, porin; Pra, pH-regulated antigen; PspC, pneumococcal surface protein; Rck, resistance to complement killing; Scl, 
streptococcal collagen-like protein; SHT, streptococcal histidine triad; Tuf, elongation factor Tu ; UspA, ubiquitous surface protein 
A; YadA, Yersinia adhesin A 
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1.2.1.2. Binding of CFH 
Alternative pathway evasion is probably the main reason why microbes acquire 
CFH or CFHL-1 on their surface. In 1988 Horstmann et al. (Horstmann et al., 1988) 
described for the first time that a microbe selectively binds human complement 
regulatory protein (CFH) and by this way evades complement mediated 
opsonophagocytosis. This was done by studying Streptococcus pyogenes serotypes 
M5, M6, M19, M24 and M28 as well as an M protein deletion mutant strain. In the 
same study the interaction between CFH and M protein was further studied by 
using a recombinant M6 protein. Thereafter the binding site on CFH for S. 
pyogenes M6 has been localized to CFH domains 6-10 (Sharma and Pangburn, 
1997) and later to the domain seven (Blackmore et al., 1998a).  
Most microbes acquire CFH via two regions of this control protein, domains 5-7 
and 18-20 (Figure 8). The reason for this specific interaction has not been 
described but it seems likely that the conserved location for the interaction on CFH 
might have a functional relevance. Although most of the known CFH-microbe 
interactions are mediated via two distinct sites in CFH, several S. pyogenes and N. 
meningitidis strains have been shown to interact with CFH via the domains 6-7 
only. More specifically, N. meningitidis has two ligands for CFH binding, Fhbp 
(Schneider et al., 2009) and NspA (Lewis et al., 2010). Two CFH ligands that have 
been found from N. gonorrhoeae interact at distinct sites of the regulatory protein. 
Por1A binds CFH via domains 6 and 18-20 while Por1B binds only domains 18-20 
(Ram et al., 1998a; Ngampasutadol et al., 2008). Also Borrelia burgdorferi uses two 
ligands for CFH binding, OspE for binding domains 18-20 (Hellwage et al., 2001; 
Alitalo et al., 2004) and BbCRASPs for 6-7 interaction (Kraiczy et al., 2001; 
Hartmann et al., 2006). Moreover, two CFH-binding ligands have been found from 
Y. enterocolitica and Streptococcus pneumoniae (China et al., 1993; Biedzka-Sarek 
et al., 2008). On the contrary, P. aeruginosa (Kunert et al., 2007) and C. albicans 
(Poltermann et al., 2007; Luo et al., 2009), use a single ligand for interacting with 
two distinct sites in CFH. Probaly also Rck of S. enterica uses two CFH interaction 
sites and the expression of the ligand in E. coli has been shown to mediate 
complement resistance (Ho et al., 2010)  
Interestingly, S. aureus Sbi and shiga toxin (Stx2) of enterohemorrhagic E. coli bind 
CFH in a unique way. From these Sbi binds domains 19-20 by not directly 
interacting with the regulator but by forming a tripartite complex with C3b (Haupt 
et al., 2008) while Stx2 binds both CFH domains 6-7 and 18-20 in fluid phase (Orth 
et al., 2009). Moreover, unlike the other CFH binding microbes, S. pneumoniae 
binds CFH via the middle part of the protein using domains 8-11, 12-14 and 19-20 
(Jarva et al., 2004; Hammerschmidt et al., 2007). 
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The ligand interacting with CFH is unknown for Haemophilus influenzae (Hallström 
et al., 2008), Fusobacterium necrophorum (Friberg et al., 2008), A. fumigatus 
(Behnsen et al., 2008), Bordetella pertussis, Bordetella parapertussis (Amdahl et 
al., 2011) and Onchocerca volvulus (Meri et al., 2002). All of these microbes 
interact at least with CFH domains 6-7 and 18-20. The microfilariae of the 
nematode Onchocerca volvulus have been shown to acquire CFH domains 8-20. 
In addition to bacteria, fungi and nematodes, CFH also binds to viral pathogens 
such as HIV-1 (Pinter et al., 1995; Stoiber et al., 1996) and West Nile virus (Chung 
et al., 2006). The constantly growing list demonstrating microbial interactions with 
CFH clearly shows that binding of CFH is a widely used innate immunity evasion 
mechanism used by a variety of pathogenic microbes.  
 
 Figure 8. Binding of CFH on microbial ligands. CFH is known to interact with several microbial ligands via domains 19-20 (left panel) and/or 5-7 (right panel).  
 1.2.1.3. Binding of host complement regulators other than C4BP and CFH 
C1inh. Complement evasion via recruitment of C1inh on the surface of at least 
three bacteria has been shown (Table 2) (Lathem et al., 2004; Marr et al., 2007; 
Grosskinsky et al., 2010). Whether these interactions could also influence other 
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host responses such as the kinin-kallikrein or coagulation systems where C1inh is 
involved is still unclear.  
Properdin. As described earlier (Section 1.1.3.1), properdin is a positive regulator 
of AP increasing the half life of surface bound C3/C5-convertases. In addition 
recent investigations have suggested that properdin plays an important role as a 
pattern recognition molecule since it binds directly (in the absence of C3b) on 
bacterial surfaces (Spitzer et al., 2007; Cortes et al., 2011). Therefore, it is likely 
that cleavage rather than binding of properdin on microbial surface would be 
beneficial for the pathogen. It has been suggested that S. pyogenes enzyme SpeB 
could cleave properdin and by this way decrease AP activation and bacterial 
opsonophagocytosis (Tsao et al., 2006). Whether decreased survival of bacteria in 
these assays was due to the action of SpeB on properdin or on C3 (shown by 
(Terao et al., 2008)) or on both remains unclear.  
S-protein (vitronectin). In 1987 Chhatwal et al. (Chhatwal et al., 1987) showed 
that several gram-positive bacteria (S. pyogenes, group C streptococci, group G 
streptococci and S. aureus) and E. coli bind S-protein and hypothesized that the 
interaction could mediate binding of the pathogen to host cells. This is probably 
the main purpose of the phenomenon especially within gram-positive bacteria that 
are resistant to the lytic effect of MAC because of the thick peptidoglycan cell wall. 
The binding of S-protein by gram-negative bacteria such as H. influenzae 
(Hallström et al., 2006) and Moraxella catarrhalis (Singh et al., 2010) has been 
described to confer to serum resistance of the bacteria.  
Clusterin. Binding of clusterin on surface of S. aureus (Partridge et al., 1996) and S. 
epidermidis (Li and Ljungh, 2001) has been described. Clusterin also binds on 
secreted microbial proteins Dengue virus NS1 protein (Kurosu et al., 2007) and S. 
pyogenes streptococcal inhibitor of complement (SIC) (Åkesson et al., 1996). 
Whether these interactions have an importance in evasion of complement MAC 
formation is unlikely at least for the investigated bacteria that are gram-positive. 
However, it is possible that the cell aggregating action of clusterin could enhance 
microbial pathogenicity. 
Factor I. In order to function as a C3b inactivator, factor I requires either a cell 
surface cofactor (CR1 or CD46) or a cofactor from the fluid phase (CFH or C4BP). 
Certain poxviruses (vaccinia-, variola- and monkeypox virus) (Sahu et al., 1998; 
Rosengard et al., 2002; Liszewski et al., 2006) and one bacterium S. aureus (Hair et 
al., 2008) all express proteins with cofactor activies for factor I.  
Receptors. CR1 receptor is a surface regulator having both cofactor and decay 
accelerating activities. Being very abundant on erythrocyte surfaces intracellular 
parasites such as Plasmodium falciparum (Spadafora et al., 2010) and Leishmania 
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major (Da Silva et al., 1989) interact with this receptor and use it for invasion into 
the host cells. In addition, DAF and MCP are both used as cellular receptors for 
viral entry into host cells (Naniche et al., 1993; Ward et al., 1994; Shafren et al., 
1997) while S. pyogenes probably uses MCP for surface attachment (Okada et al., 
1995; Giannakis et al., 2002). In contrast, CD59 has been detected from microbial 
surfaces indicating that this GPI-anchored protein can be transferred from host cell 
to the microbial surface (Rautemaa et al., 1998; Rautemaa et al., 2001).  
Table 2. Microbial acquisition of host complement regulatory proteins others than CFH and 
C4BP 
  
Protein Microbe Ligand Reference 
C1inh Bordetella pertussis Vag8  (Marr et al., 2007; Marr et al., 2011) 
 Borrelia recurrentis CihC (Grosskinsky et al., 2010) 
 Escherichia coli StcE (Lathem et al., 2004) 
S-protein Haemophilus influenzae  Hsf (Hallström et al., 2006) 
 Moraxella catarrhalis UspA2 (Singh et al., 2010) 
 several bacteria           ? (Chhatwal et al., 1987) 
Clusterin Staphylococcus 
 
            ? (Partridge et al., 1996) 
 Streptococcus pyogenes SIC (Åkesson et al., 1996) 
Factor I Staphylococcus aureus ClfA (Hair et al., 2008) 
CR1 Leishmania major  ? (Da Silva et al., 1989) 
 Plasmodium falciparum PfRh4 (Spadafora et al., 2010; Tham et al., 2010) 
CD59 Escherichia coli  ? (Rautemaa et al., 1998) 
 Helicobacter pylori  ? (Rautemaa et al., 2001) 
DAF Coxsackie A 21 virus  ? (Shafren et al., 1997) 
 Echovirus 7  ? (Ward et al., 1994) 
MCP Measles virus Hemagglutinin (Naniche et al., 1993; Manchester et al., 2000) 
 Streptococcus pyogenes M protein (Okada et al., 1995) 
Abbreviations: CihC, complement inhibition; ClfA, clumping factor A; Hsf, Haemophilus surface fibrils; PfRh, reticulocyte-binding–
like homolog protein; SIC, Streptococcal inhibitor of complement; StcE, secreted protease of C1 esterase inhibitor from EHEC; 
UspA, ubiquitous surface protein A; Vag, autotransporter encoded by virulence-activated gene 8  
1.3 Examples of complement evading microbes  1.3.1 Loa loa 
 
The “eye worm” was first described in medical literature in 1770 and 1777 when 
occasional subconjunctival migration of a filarial worm was reported as reviewed 
earlier (Grützig and Jennes, 1977). The African eye worm, Loa loa, belongs to the 
phylum Nematoda or roundworms having distinguishing characteristics such as 
cylindrical shape of body, longitudinal musculature and a thick acellular cuticle 
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(Hickman et al., 2001). The adult worms live in human subcutaneous tissues, 
reproduce and release microfilariae in peripheral blood or spinal fluid, urine, saliva, 
or into the alveolar space. The adult females are 40-70 mm long while the males 
are 30-34 mm. The produced microfilariae are 250-300 µm long and they possess a 
loosely bound sheath like a bag around each microfilarium. In addition to its size, it 
can be distinguished from other blood dwelling filarial worms by the staining 
characteristics, the appearance of the densely packed nuclei that extend to the tip 
of the rouded shape tail, and the presence of the sheath (Cook and Zumla, 2004). 
When isolated from human blood and examined under microscope they make 
whip-like movements and the viability is maintained up to two weeks when stored 
on ice (unpublished observation).  
 1.3.1.1. Loa loa life cycle  
The blood dwelling microfilariae are ingested during a blood meal by a dipteran 
female vector (Chrysops spp.) (Figure 9). The main vectors that transmit human 
loiasis are Tabanidae flies belonging to species Chrysops silacea and Chrysops 
dimidiate (deer flies, mango flies, mangrove flies) (Gouteux et al., 1989). After 
entering the midgut of the vector the microfilariae lose their sheaths (Padgett and 
Jacobsen, 2008). Thereafter they penetrate the gut wall and move to the so called 
fat body in the abdomen of the arthropod vector for maturation. Here they 
undergo two molts into stage 1 and 2 larvae, differentiate further and increase in 
length from approximately 300 µm up to 700 µm. The third stage infective larvae 
(L3) are liberated and start to migrate from the abdomen to the head of the insect. 
Here the L3 infective larvae can be found from the proboscis (mouth parts) of the 
vector having a size of approximately 2 mm. The larvae are transmitted into the 
human body when the vector feeds again. The development in the vector takes 
approximately 8-10 days (Orihel and Lowrie, 1975) while in human subcutaneous 
tissues the larvae develop into adults within approximately 1 year and can live in 
humans up to 15 years (Gems, 2000).  
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 Figure 9. Loa loa life cycle. Loa loa L3 stage larvae enter human body through the bite wound when the vector Chrysops spp. takes a blood meal. Loa loa develop in subcutaneous tissues and produce sheathed microfilariae that can be found in the peripheral blood. Microfilariae enter the vector when it feeds and thereafter the larvae lose their sheaths (L1 larvae). There they develop into L2 and L3 larvae. The L3 larvae can be found from the mouth parts of the vector. 
 1.3.1.2 Distribution of Loiasis 
Within its current endemic regions in Western and Central Africa the prevalence of 
loiasis can be very high being over 40% in certain areas (Boussinesq and Gardon, 
1997; Zouré et al., 2011) (Figure 10). During human loiasis microfilariae live in 
blood (microfilaremia) and the number of microfilariae in peripheral blood has 
diurnal periodicity providing an explanation why they are effectively transmitted 
via the day biting vector only. In addition to parasite adaptation to the feeding 
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habits of the vector, the effective transmission is facilitated by the high density of 
Chrysops spp. in endemic areas. The vector mainly attacks moving objects and the 
bite is painful. Therefore the feeding is frequently interrupted which in turn 
increases the frequency of attacks and thereby the frequency of exposure to the 
parasite. Although few Chrysops flies carry Loa loa infective larvae (e.g. 0.7 % of 
Chrysops silacea in South-West Cameroon) the parasite load in the infected vector 
is high and the transmission becomes therefore effective (Nanduri and Kazura, 
1989; Wanji et al., 2002). There are no effective methods to control transmission 
of loiasis. However, drainage of marshy areas where Chrysops flies live can 
decrease the number of the vector. Personal protection such as wearing light-
colured clothing and usage of insect repellent has been shown to reduce bites by 
the flies.   
 Figure 10. Distribution of loiasis. Loiasis is endemic in rain forest areas of Western and Central Africa (marked with grey). High risk level of loiasis is found at least in 10 countries. Figure modified from (Zouré et al., 2011).  1.3.1.3 Loiasis  
In addition to being frequently asymptomatic loiasis can cause symptoms such as 
episodes of Calabar swellings (subcutaneous, non-tender oedemas that are often 
itching), subcutaneous and subconjunctival migration of adult worms (history of 
eyeworm), pruritus, and secondary dermal lesions (Noireau et al., 1990). Serious 
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sequelae such as renal complications have also been reported (Pakasa et al., 1997). 
Hypersensitivity reactions are most common within visitors to endemic areas 
whereas hypersensitivity within residents of endemic areas is not as frequent and 
less severe (Nutman et al., 1986). Loiasis is a disease of public health importance 
mainly because of the negative effects during ivermectin treatment that is used to 
control onchocerciasis (river blindness) in central Africa. Especially patients with 
high blood concentrations of Loa loa microfilariae (approximately 15,000 
microfilariae/ml or more) have been reported to develop severe and sometimes 
fatal encephalopathic reactions after treatment with ivermectin (Chippaux et al., 
1996; Gardon et al., 1997). It has been estimated that some 14.4 million people 
live in high risk areas where the prevalence of loiasis varies between 20% and 40%. 
Most of this area also overlaps with the distribution of onchcerciasis and therefore 
predispose these people to severe adverse reactions when treated with ivermectin 
(Zouré et al., 2011). 
 
1.3.1.4 Host immunity and immune evasion by Loa loa  
It is known that some of the Loa loa infected individuals carry adult worms but are 
amicrofilaremic while some individuals have considerable microfilaremia. In 
endemic areas where prevalence of loiasis is high nearly all adults have antifilarial 
antibodies. The antibody positivity is gained during early childhood since the 
percentage of children that are over five years old and positive for antifilarial IgG, 
IgM and IgE antibodies is similar to the corresponding percentage of adults 
(Goussard et al., 1984). In these areas amicrofilaremic persons may have high IgG 
class antibody titers indicating that antibody-mediated mechanisms could be 
important in controlling microfilaraemia in loiasis (Pinder et al., 1988). Moreover, a 
subsequent study has suggested that these antimicrofilaria IgG antibodies are 
effective in mediating adherence of host neutrophils on microfilariae and that both 
CP and AP have important roles in it (Pinder et al., 1992).  
In endemic areas loiasis patients are often chronically infected.  Recent studies has 
shown that within these patients Loa loa causes parasite-specific downregulation 
of T-cell responses more often than within Loa loa infected travelers that are more 
likely to have hypersensitivity reactions such as Calabar swellings (Steel et al., 
2012). The high prevalence of chronic infection could partially explain the high 
transmission rate of loiasis in endemic areas.  It is evident that the sheath and/or 
the underlying thick cuticle surrounding Loa loa microfilariae are most probably 
protective against direct complement lysis but it is still unclear how the parasites 
avoid host innate immune defenses until they are transmitted to the vector.  
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1.3.2 Streptococcus pyogenes (Group A streptococcus)  1.3.2.1 Infections  
S. pyogenes is the causative agent of variety of infectious diseases. The most 
common disease caused by S. pyogenes is tonsillitis characterized by sore throat, 
fever, and white patches on inflamed tonsils. Also streptococci belonging to groups 
C and G can cause tonsillitis. Some S. pyogenes strains (certain M protein 
serotypes, typing being described in chapter 1.3.2.2) cause pharyngitis while some 
others cause mainly skin infections. Another S. pyogenes disease, scarlet fever, is 
caused by strains that produce pyrogenic exotoxins responsible for the systemic 
symptoms recognized by rash and strawberry tongue seen during the disease 
(Cunningham, 2000).  
S. pyogenes skin infections impetigo and erysipelas affect the superficial layers of 
the skin while cellulitis affects subcutaneous tissues (Bisno and Stevens, 1996). In 
addition to S. pyogenes, streptococci belonging to groups B, C, and G can also 
cause erysipelas and cellulitis (Binnick et al., 1980; Eriksson et al., 1996).  
Streptococcal toxic shock- or toxic shock-like syndrome (TSS, STSS or TSLS) was first 
described in 1987 and was shown to be similar to S. aureus toxic shock syndrome 
(Cone et al., 1987). Streptococcal pyrogenic exotoxin, SpeA, expressed by certain S. 
pyogenes strains is associated with this complication characterized by hypotension 
and multi organ failure (Hauser et al., 1991).  
Streptococcal infection may also lead to an even more severe complication called 
necrotizing fasciitis where S. pyogenes is more commonly known by the name 
“flesh eating bacterium” (Kaul et al., 1997). Localized S. pyogenes infections may 
also cause complications such as septicemia, pneumonia, or meningitis.  
Sometimes S. pyogenes infections may lead to post-infectious sequelae such as 
acute glomerulonephritis or rheumatic fever. Microbial factors such as type of M 
protein (Lindberg and Vosti, 1969), production of SpeB or streptokinase, or 
induction of the C3-nephritic factor (C3Nef, autoantibody against C3) by the so-
called nephritogenic strains have been suggested to play a role in the pathogenesis 
of the post-streptococcal glomerulonephritis (PSGN) (Villarreal et al., 1979; 
Johnston and Zabriskie, 1986; Poon-King et al., 1993). C3Nef generated 
occasionally during streptococcal infections can lead to acute glomerulonephritis 
by causing stabilization of C3 convertases on host cells thus decreasing the pace of 
their decay leading to excess complement activation (Fremeaux-Bacchi et al., 
1994). Rheumatic fever is an serious post-infectious condition with symptoms 
including fever, arthritis, and inflammation in cardiac valves leading to tissue 
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damage and often valve leakage (Stollerman, 1975). Streptococcal infections have 
also been associated in some studies with other immunologically mediated 
diseases such as Tourette´s syndrome, tics (Cunningham, 2000), psoriasis (Telfer et 
al., 1992), and narcolepsy (Aran et al., 2009). The associations, however, are 
controversial.  1.3.2.2 Structure and classification of S. pyogenes  
As a gram-positive bacterium, S. pyogenes has a cytoplasmic membrane covered 
with a thick peptidoglycan layer with a number of different surface proteins (Figure 
11). Within the genus Streptococcus the round shaped cells are typically found in 
chains or pairs - hence the name. The net-like structure of peptidoglycan is based 
on polymerization of the repeating disaccharide, N-acetylmuramic acid-(β1-4)-N-
acetylglucosamine and cross linking of the polymers is mediated by dialanine 
bridges (Munoz et al., 1967). The peptidoglycan layer is surrounded by a capsule 
composed of hyaluronic acid (N-acetylglucosamine and glucuronic acid) which is 
poorly immunogenic in humans (Kendall et al., 1937). When observed by electron 
microscopy, the capsule is penetrated by filamentous structures: small fibrils, 
thicker and longer fimbriae or pili (Fischetti, 1989; Mora et al., 2005).  
The ability of certain streptococci to cause hemolysis of red blood cells was first 
noted by Alexander Mamorek in 1895 as reviewed here (Cinader and Pillemer, 
1950). In a throat swab sample cultured on blood agar plates S. pyogenes appears 
as β-hemolytic colonies unlike the normal oral flora. Differentiation of S. pyogenes 
from other β-hemolytic streptococci is based either on its sensitivity to bacitracin 
or on agglutination by antiserum against the group A specific carbohydrate 
(Lancefield, 1933) composed of N-acetylglucosamine and rhamnose (Krause and 
McCarty, 1961). Within the S. pyogenes species the bacteria can be classified 
according to the antigenic differences in the main surface protein, M protein 
(Lancefield, 1928). Currently, instead of M-typing based on antisera, also M protein 
gene emm typing is widely used. This is based on sequencing of the 5´ end of the 
emm gene that encodes the hypervariable (HVR) region of M protein responsible 
for the M type specificity (Beall et al., 1996; Facklam et al., 1999). Other 
classifications such as typing according to the T antigen or the substance increasing 
serum opacity (opacity factor, OF) are also used in research and epidemiology as 
reviewed here (Cunningham, 2000). M protein is one of the most diverse surface 
proteins of S. pyogenes and it has been clearly shown that antibodies against a 
certain M protein are protective against infections by the S. pyogenes strains 
carrying that M type (Lancefield and Todd, 1928).  
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M protein is a 50-60 nm long fibrillar membrane anchored molecule having a 
dimeric α-helical coiled coil structure (Figure 11) (Phillips et al., 1981; McNamara 
et al., 2008; Macheboeuf et al., 2011). The carboxyl-terminal end that anchors the 
molecule onto the cell membrane consists of a hydrophobic domain and a 
conserved LPXTGX motif common for most gram-positive surface proteins 
(Fischetti et al., 1990). The extracellular region close to the membrane is called a 
proline- and glycine-rich region (Pro/Gly). Further out from the membrane are first 
D-repeats followed by C-repeats that all contain conserved amino acid sequence 
repeats common in all S. pyogenes serotypes and typical for coiled coil structures. 
The middle B-repeat region varies between different S. pyogenes serotypes while 
the region furthest from the membrane is the amino-terminal A-repeat region 
containing the serotype specific HVR region. This is the target for the protective 
antibody production against S. pyogenes infections (Jones et al., 1985; 
Hollingshead et al., 1986; Fischetti et al., 1988; Mouw et al., 1988; Fischetti, 1989). 
The number of repeating units in the A and B regions are mainly responsible for 
the size variation among different M proteins (Hollingshead et al., 1987). Division 
of M proteins into class I and class II molecules is based on the recognition of 
specific antibodies against the C-repeat region. The serotypes expressing the class I 
M protein are OF negative while the class II M protein serotypes are OF positive 
(Bessen et al., 1989; Bessen and Fischetti, 1990). Although overall organization of 
M protein is generally conserved, major differences exist such as the size and 
number of A and B repeats. Therefore M proteins can be divided in patterns A-E 
according to these differences as reviewed here (Smeesters et al., 2010). 
The emm gene coding the M protein is positively regulated by the mga-regulon 
(multiple gene regulator in group A streptococcus)(Caparon and Scott, 1987) that 
also regulates transcription of scpA gene of C5a peptidase (or ScpA) (Simpson et 
al., 1990). Furthermore, the locus regulates transcription of genes encoding S. 
pyogenes M-like proteins (mrp, fcr and enn) (Podbielski et al., 1995), OF 
(McLandsborough and Cleary, 1995) and SIC (Kihlberg et al., 1995). Expression of 
M protein depends on the growth phase of the bacteria. For example the emm6 
gene is most actively expressed in late log phase or after 8 h growth and is 
increased by elevated CO2 levels (Caparon et al., 1992), NaCl2 and temperature, 
while it is decreased during vigorous gas exchange and iron limitation (McIver et 
al., 1995). Although the emm gene encoding the M protein (type I or II) is present 
in the chromosome of all known S. pyogenes strains the presence of the genes 
encoding the other factors that are in the control of the regulon varies between 
the strains (Bessen and Hollingshead, 1994; Hollingshead et al., 1994). M protein is 
an important virulence factor of S. pyogenes as it is needed for bacterial adhesion 
and invasion and is required for resistance to complement attack and phagocytosis 
(Scott et al., 1986; Perez-Casal et al., 1992).   
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1.3.2.3 Bacterial colonization 
Several S. pyogenes surface proteins mediate adhesion to host cell surfaces while 
some of these interact with host plasma proteins. Moreover, certain secreted 
enzymes and toxins are involved in bacterial invasion and spread between host 
tissues. Several virulence factors are not constitutively expressed but are induced 
by environmental changes such as changes in oxygen levels and pH. When present, 
these factors significantly assist the bacterial colonization and thereby influence 
the pathogenicity of the microbe as reviewed here (Nobbs et al., 2009).  
 
 Figure 11. Virulence factors on S. pyogenes surface. M protein and streptococcal collagen-like (Scl) protein are surface structures penetrating through the thick peptidoglycan layer and the cell membrane having a cytoplasmic tail while lipoteichoic acids (LTA) are attached to the outer leaflet of the membrane. M protein has mostly fibrillar coiled-coil structure and its most amino-terminal region is the hypervariable region (HVR) having considerable sequence dissimilarity between the S. pyogenes emm types. Picture modified from (Fischetti, 1989; Xu et al., 2002; Weidenmaier and Peschel, 2008). 
 
Adhesion is the first step essential for S. pyogenes colonization. Bacterial 
colonization is a dynamic process where the microbe has to face challenges such as 
nutritional and other environmental requirements including pH, oxygen level, and 
the attack of the host immune system. If the growth conditions are unfavorable 
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the bacterium may detach from the surface at this point and retry colonization 
elsewhere as reviewed here (Nobbs et al., 2009). The surface of the bacterium is 
coated with fibrils such as M proteins and lipoteichoic acids (LTA) (figure 11) that 
mediate adhesion onto the epithelial cell surfaces (Beachey and Ofek, 1976; Okada 
et al., 1994).  
Some S. pyogenes strains have been shown to interact with extracellular matrix 
(ECM) components such as fibronectin or fibrinogen thus promoting bacterial 
colonization. These protein adhesins include for example FBP54 (Courtney et al., 
1994), Protein F/SfbI (Hanski and Caparon, 1992; Hanski et al., 1992; Talay et al., 
1994), PFBP (Rocha and Fischetti, 1999), OF/SfbII, (Kreikemeyer et al., 1995), 
streptococcal surface GAPDH (SDH or Plr binds also plasminogen, lysozyme, 
myosin) (Pancholi and Fischetti, 1992), M protein (Carlsson et al., 2005; 
Macheboeuf et al., 2011) and streptococcal collagen-like protein 1, Scl1 (Figure 11) 
(Caswell et al., 2010). Including the proteins mentioned above, over 35 surface 
associated S. pyogenes adhesins have been described to interact with fibronectin 
or fibrinogen as well as with several other host molecules such as collagen, 
plasminogen, plasmin, laminin, immunoglobulins, and complement proteins as 
reviewed here (Nobbs et al., 2009).  
 1.3.2.4 Invasion  
In order to invade into deeper tissues, S. pyogenes expresses virulence factors that 
break host barriers themselves or activate host enzymes. S. pyogenes 
streptokinase, plasminogen-binding group A streptococcal M-like protein (PAM), 
and streptococcal surface enolase (SEN, Eno) have been shown to interact with 
plasmin/plasminogen. It has been suggested that PAM is responsible for binding of 
plasminogen on S. pyogenes surface causing activation of plasminogen by 
streptokinase leading to breakage of physical host barriers and migration of the 
bacteria into the tissues (Reddy and Markus, 1972; Berge and Sjöbring, 1993; 
Pancholi and Fischetti, 1998). A secreted cysteine protease SpeB expressed by 
various S. pyogenes strains cleaves human fibronectin and degrades S-protein 
(vitronectin) that can facilitate microbial invasion and spread between tissues 
(Kapur et al., 1993). Invasion into cultured human cells by certain S. pyogenes 
strains has been described to be mediated by M protein (Fluckiger and Fischetti, 
1997) and Scl1 (Caswell et al., 2010). Whether this occurs in vivo is still unclear. 
However, the bacteria surviving inside host cells have been hypothesized to be the 
reservoir of S. pyogenes in recurrent infections (Österlund et al., 1997). 
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1.3.2.5 Toxins  
Several S. pyogenes strains secrete toxins that are involved in systemic toxicity. 
Some of these are produced by most of the strains (e.g. streptolysin O, SLO) and 
some by strains associated with certain streptococcal infections or symptoms in 
streptococcal syndromes. These include superantigens that over stimulate T-cells 
by binding nonspecifically to major histocompatibility complex class II (MHCII) 
molecules outside the peptide-binding site and simultaneously to the Vβ chain of 
the T-cell receptor (TCR). The overstimulation liberates large amounts of 
inflammatory cytokines leading to a systemic inflammatory reaction with multiple 
symptoms. These kinds of superantigens include, for example, streptococcal 
pyrogenic exotoxins (e.g. SpeA, SpeB, SpeF, SpeJ, SpeG, SpeH), streptococcal 
mitogenic exotoxins Z (SMEZ, SMEZ-2, SMEZ-3) (Fast et al., 1989; Norrby-Teglund 
et al., 1994a; Norrby-Teglund et al., 1994b; Kamezawa et al., 1997; Proft et al., 
1999; Gerlach et al., 2000), and streptococcal superantigen (SSA) (Mollick et al., 
1993). The first streptococcal pyrogenic exotoxin was isolated from blood and 
urine of a patient with scarlet fever and the toxin was therefore called scarlet fever 
toxin (Trask and Blake, 1924) while the streptococcal superantigen has also been 
described from S. pyogenes strains causing streptococcal toxic shock-like syndrome 
(Mollick et al., 1993). SLO is a hemolysin that causes damage to the target cell by 
forming large transmembrane pores analogous to complement C5b-9 (Bhakdi et 
al., 1985) and permits another toxin, S. pyogenes NAD glycohydrolase (NADase, 
SPN), to enter the host cell (Madden et al., 2001). This in turn induces apoptosis of 
the target cell (Bricker et al., 2002).  
 1.3.2.6 Immune escape 
Facing the immune system is clearly the biggest challenge for microbial survival in 
the human body. The innate immunity threatening bacteria consists mainly of the 
complement system and phagocytic cells. These players form the first line defense 
against the invading streptococci. In order to survive and multiply a bacterium has 
to produce virulence factors evading these systems (Figure 12). Immune escape by 
S. pyogenes involves several virulence factors. For example, interference with 
opsonophagocytosis is mediated via secreted cysteine proteases Mac-1 (also 
known as IdeS or MspA) (von Pawel-Rammingen et al., 2002), Mac-2 (Söderberg et 
al., 2008), SpeB, and endoglycosidase EndoS (Collin and Olsen, 2001), that all 
cleave IgG bound to the bacterial surface. Also, by expressing a surface bound C5a 
cleaving enzyme, C5a peptidase, the bacterium can inactivate complement-
mediated chemotactic activity and subsequently inhibit opsonophagocytosis and 
thereby lower number of phagocytes at the site of invasion (Wexler et al., 1985). 
Furhermore, several S. pyogenes M proteins (Sir, Arp, Mrp) and SfbI have been 
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shown to bind IgG and/or IgA through the Fc part of the antibodies thereby 
putatively avoiding Ig-mediated opsonisation (Stenberg et al., 1992; Medina et al., 
1999). 
 
 Figure 12. Streptococcus pyogenes immune escape. Several S. pyogenes factors act against the host immune system. SpeB, and EndoS cleave IgG while C5a-peptidase interferes with chemotaxis by cleaving C5a. SIC binds to C5b-7 and prevents MAC formation. M protein binds complement regulators C4BP and CFH while Scl1 binds only CFH. These interactions promote complement resistance of S. pyogenes. EndoS, endoglycosidase S; Scl1, streptococcal collagen-like protein 1; SIC, streptococcal inhibitor of complement; SpeB, streptococcal pyrogenic exotoxin B;  
 
S. pyogenes adhesion on keratinocytes is mediated via the interaction between the 
bacterial M protein and the complement regulator MCP on the cell surface (Okada 
et al., 1995). The binding site for the M6 protein on MCP is located between 
domains 3 and 4 at a site distinct from the cofactor activity region of the molecule 
(Giannakis et al., 2002). In addition to bacterial adhesion, it has been suggested 
that the M protein interaction with MCP on human lung epithelial cells promotes 
intracellular entry of S. pyogenes (Rezcallah et al., 2005). On the other hand, on T-
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cells MCP-M protein contact induces generation of regulatory T-cells leading to 
down regulation of T-cell responses (Price et al., 2005).  
Several S. pyogenes strains, but not all, bind host fluid phase complement 
regulators CFH and C4BP to restrict complement activation targeted onto the 
bacterial surface. C4BP binding has been demonstrated from several different S. 
pyogenes strains and the interaction is most presumably mediated via the HVR of 
Ig-binding M proteins (Stenberg et al., 1992; Stenberg et al., 1994; Thern et al., 
1995; Morfeldt et al., 2001). The M protein-binding site on C4BP α-chain has been 
localized to the interface between domains one and two (Accardo et al., 1996; 
Villoutreix and Dahlback, 1998) and is overlapping, but not identical, with the 
binding site for C4b (Blom et al., 2000a). Since C4BP has a total of seven α-chains 
(and perhaps due to only partial overlap) this interaction is not supposed to 
interfere with C4BP regulatory activity. This is supported by a study showing that 
the interaction between C4BP and M22 protein contributes to phagocytosis 
resistance (Berggård et al., 2001). It has also been postulated that certain M 
proteins that do not bind C4BP bind fibrinogen so that M protein-bound fibrinogen 
could inhibit complement via the classical pathway similarly to C4BP (Carlsson et 
al., 2005).  
Acquisition of CFH onto S. pyogenes is mediated at least by three different surface 
proteins, indicating that CFH binding is important in S.pyogenes immune evasion. 
Among these, the interaction between CFH and S. pyogenes M proteins has been 
most extensively studied. The binding site for CFH on M6 protein was first localized 
to the conserved C-repeat region (Fischetti et al., 1995). Later, binding studies with 
whole bacteria and their M protein lacking C-repeat region was used to locate the 
binding site outside the C-repeat, probably to the HVR (Sharma and Pangburn, 
1997). Also CFHL-1 binding studies to purified M5 and chimeric M5-emm22 
proteins (Johnsson et al., 1998) indicates that the HVR interacts with CFH. In any 
case it has been shown that CFH binding via M protein leads to AP evasion and 
phagocytosis resistance of S. pyogenes (Horstmann et al., 1988). According to 
current knowledge the binding site for M protein on CFH is located at the domain 
seven (Blackmore et al., 1998a) where is also the site for the common Y402H 
polymorphism (see section 1.1.3.1.).  
The second S. pyogenes protein interacting with CFH and CFHL-1 is Fba 
(Pandiripally et al., 2002) that also mediates invasion of S. pyogenes into cultured 
human cells (Terao et al., 2001). Scl1 is the third S. pyogenes protein that has been 
found to interact with CFH. Binding has been shown with two M types, M6 and 
M55, (Caswell et al., 2008) and the binding site for Scl1 on CFH is located within 
domains 18-20 (Reuter et al., 2010). 
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In addition to acquiring host complement regulators some S. pyogenes strains 
express SIC protein that directly inhibits complement activation. This protein 
inhibits MAC formation on the bacterial surface (Åkesson et al., 1996) by binding to 
C5b-7 and C5b-8 complexes in fluid phase (and to a minor extent to C5b-9 as well) 
(Fernie-King et al., 2001). Moreover, the cysteine protease SpeB that cleaves IgG 
and fibronectin degrades also S-protein (vitronectin) (Kapur et al., 1993). However, 
as previously mentioned, it is unlikely that cleavage of the TP components or 
regulators has a significant role in complement evasion of the gram-positive 
bacterium.  
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2 AIMS OF THE STUDIES 
 
The aims of the studies in this thesis were to analyze the following four issues: 
 
1. Can capture of host CFH by a pathogen be observed in vivo? 
 
2. Does the common amino acid substitution Y402H in CFH domain seven 
affect opsonization, complement evasion, and multiplication of S. 
pyogenes in vitro?  
 
3. Could complement evasion and survival of S. pyogenes in human blood 
be inhibited using a non-functional recombinant CFH fragment that 
inhibits bacterial CFH binding? 
 
4. Does the polymorphism Y402H of CFH contribute to susceptibility of 
human individuals to streptococcal infections? 
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3 MATERIALS AND METHODS 
 
3.1 Materials  
 3.1.1 Proteins and antibodies 
 
CFH and C3 proteins were isolated from EDTA plasma obtained from healthy 
consented laboratory workers using methods modified from Koistinen et al. 1989 
(Koistinen et al., 1989) (study II). First the plasma was mixed with buffer A (Table 
3), 0.5 mM phenylmethylsulfonyl fluoride (PMSF), and 0.2 M benzamidine followed 
by precipitations with 10% and 30% polyethylene glycol 4000 (PEG) in buffer B, 
respectively. The second precipitate was diluted in buffer C, run through anion 
exchange (Q-sepharose-FF) column, and eluted with salt gradient (from 100% 
buffer C to 100% buffer C2). The eluted fractions containing C3 were then 
precipitated again with 30% PEG in buffer B and then dissolved in buffer C while 
eluted fractions containing CFH were pooled and stored in -70°C. After dissolving 
the precipitate, C3 sample was run through cation exchange (SP-sepharose-FF) 
column where the proteins were eluted with salt gradient (buffers D and D2).  
 
Table 3. Special buffers used in CFH isolation (study II) 
Buffer Compounds 
A 1 M KH2PO4; 0.2 M EDTA; 0,2 M benzamidine; pH 7.4 
B 
 
0,1 M NaH2PO4; 15 mM EDTA; 0.15 M NaCl; 0.01 M benzamidine; 0.02% 
NaN3; pH 7.4 
C 0.015 M NaH2PO4; 5 mM EDTA; 0.025 M NaCl; 0.02% NaN3, pH 8.0 
C2 0,015 M NaH2PO4; 5 mM EDTA; 0.4 M NaCl; 0.02% NaN3, pH 7.5 
D 0.015 M NaH2PO4; 5 mM EDTA; 0.025 M NaCl; 0.02% NaN3, pH 6.0 
D2 0.015 M NaH2PO4; 5 mM EDTA; 0.4 M NaCl; 0.02% NaN3, pH 6.0 
E 0.02 M NaH2PO4; 2 mM EDTA; 0.02% NaN3, pH 6.0  
E2 0.02 M NaH2PO4; 2 mM EDTA; 0.02% NaN3; 0.35 M NaCl, pH 6.0 
F 0.01 M NaH2PO4; 5 mM EDTA; 0.02 M NaCl, pH 7.5 
F2 0.01 M NaH2PO4; 5 mM EDTA; 0.3 M NaCl, pH 7.5 
PBS1 75 mM phosphate-buffered saline, pH 7.0 
PBS2 2 M NaCl in 75 mM phosphate-buffered saline, pH 7.0 
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Stored CFH fractions were thawed and then precipitated again with 30% PEG and 
dissolved in buffer E. Some CFH was lost since all the precipitate could not be 
dissolved easily. The solution was centrifugated and run through a cation exchange 
(SP-sepharose-FF) column using salt gradient elution (buffers E and E2). Thereafter, 
the CFH containing fractions were mixed and run again through a smaller volume 
cation exchange (SP-sepharose) column and eluted with PBS containing 0.5 M 
NaCl. CFH was then separated from high and low molecular weight contaminants 
using gel filtration (Sephacryl S-300) in E buffer. Finally, the sample was run into 
MonoQ anion exchange column (buffers F and F2) using ÄKTA purification system 
and thereafter dialyzed against PBS. 
Detection of which elution fractions contained CFH or C3 was done by dot-blotting 
using specific CFH or C3 antibodies with horseradish peroxidase (HRP) conjugated 
secondary antibody detection (Table 4). Before use, all the proteins were dialyzed 
against PBS and run by sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) for Western blotting and Coomassie blue or silver staining. The purities 
of different CFH allotypes were estimated to be similar in the stained SDS-PAGE 
gels. Protein concentrations were measured using BCA (bicinchoninic acid) protein 
assay reagent (Thermo Fischer Scientific). Isolated and 125I-labeled proteins were 
stored at -70°C (CFH) or on ice (C3) before use.  
 
Table 4. Purchased and/or obtained antibodies and other proteins 
Protein Supplier Antibody supplier 
Secondary 
antibody* 
CFH Calbiochem goat α-CFH Calbiochem donkey α-goat 
factor I Calbiochem rabbit α-C1q Dako goat α-rabbit 
CR1  T Cell Sciences  mouse α-MBL  Statens Serum Institute rabbit α-mouse 
C4b Calbiochem goat α-C4 Cappel donkey α-goat 
iC3b Calbiochem rabbit α-C3c Dako goat α-rabbit  
  sheep α-C3 ICN Biochemicals donkey α-sheep 
C5 Quidel goat α-C5 Quidel donkey α-goat 
  mouse α-C5b-9 Quidel rabbit α-mouse 
C4BP Prof. A. Blom; rabbit α-C4BP  A. Blom goat α-rabbit  
C4BP 
 
Complement 
Technologies    
  α-C9 neoepitope Hycult Biotech - 
    goat anti-C7 Cappel donkey α-goat 
* Supplier for the antibodies conjugated with horseradish peroxidase (HRP) was Jackson Immunoresearch; 
supplier for Alexa 488-conjugated antibodies was Molecular Probes 
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C3b was prepared from plasma-purified C3 (study I) as described earlier (Koistinen 
et al., 1989) by incubating C3 with trypsin (Sigma genosys) at a ratio of 100:1 
(w/w). C4b was purchased from Calbiochem. To obtain iC4b (study I), C4b was 
inactivated by incubating 100 µg/ml of the protein with 2 µg/ml of factor I, 1 µg/ml 
of C4BP and 5 µg/ml of soluble CR1 (Table 4) for 2 h at +37°C. Plasma purified C4BP 
in complex with protein S and the rabbit α-C4BP antibody were obtained as a kind 
gift from Prof. Anna Blom (Department of Laboratory Medicine, Medical Protein 
Chemistry, Lund University, Sweden). 
 3.1.2 Recombinant proteins  
 
The following CFH recombinant constructs having the domains 5-7 of full length 
CFH were made: CFH5-7(402Y), CFH5-7(402H) and CFH5-7(402H/420H) (studies II 
and III). First, a cDNA library was used as a template for PCR amplification by using 
specific primers (Table 5). The PCR amplicons were run on a 1% agarose gel, 
extracted from the gel (Qiagen), inserted and ligated into pCR2.1 vectors and 
further transformed into competent E. coli cells using a chemical transformation 
procedure (TOPO TA Cloning®, Invitrogen). Transformants were selected on the 
next day according to blue/white colony screening. Selected bacteria were grown 
in appropriate media, the plasmids were isolated for sequencing using a Plasmid 
DNA purification kit (Qiagen), after which the constructs were recloned into 
pPICZα vectors. Thereafter, mutagenesis to CFH5-7 DNA was performed by using a 
Site-directed Mutagenesis kit (Stratagene). In corrigendum of study II mutagenic 
primers were used to obtain CFH5-7 constructs CFH5-7(402Y) and CFH5-7(402H) 
both having an insertion of a the three amino acid stop-codon. In study II a single 
amino acid mutation in CFH5-7(402H) was done to obtain the double mutant 
CFH5-7(402H/420H) (Table 5). The vector was isolated from the selected colonies 
for sequencing and transformed into Pichia pastoris X-33 strains. Methanol 
induction was used for protein expression and subsequently the supernatants of 
the P. pastoris expression media were harvested at 96 h, filtered and run through 
heparin affinity chromatography on ÄKTA purification system using salt gradient 
elution (buffers PBS1 and PBS2) (Table 3).  
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Table 5. DNA and oligonucleotides used (study II*, III#) 
Name Supplier Sequence 
pPICZαC vector* Invitrogen ¶ 
pPICZαA vector*,# Invitrogen ¶ 
pPCR2.1 vector*,# Invitrogen ¶ 
SCR5 forward primer 
for pPICZαC vector* 
Sigma-
Genosys 
GAATTAGAAAAATCATGTGATAA 
 
SCR5 forward primer 
for pPICZαA vector *,# 
Sigma-
Genosys 
GAATTCGAAAAATCATGTGATAATCC 
 
 
SCR7 reverse primer*,# 
 
Sigma-
Genosys 
TTCTAGAGCTGTTTGACACGGATGCATC 
 
Y420H mutagenic 
primer* 
 
Sigma-
Genosys 
CCATCCTGG(T/C)CACGCTCTTCCAAAAGCGCAGA 
 
Y402H mutagenic 
primer§ 
 
Sigma-
Genosys 
CCCTGTACAAACTTTCTTCCAT(A/G)ATTTTGATTATATCCATTTTC 
 
mutagenic primer with 
a stop codon§ 
 
Sigma-
Genosys 
GATGCATCCGTGTCAAAACA(TGA)GCTCTAGAA 
 
human liver cDNA 
library*,¶ 
Stratagene 
 
 
*used in study II, #used in study III, §corrigendum of Study II, ¶can be found in suppliers manual  3.1.3 Microbes  
 
S. pyogenes strains (studies II and III) were kindly provided by Dr. Jaana Vuopio 
from National Public Health strain collection (National Institute for Health and 
Welfare, Helsinki, Finland) or Dr. Wezenet Tewodros (Spartan Health Science 
University, Spartan Medical School, St. Lucia, West Indies) or obtained from the 
Helsinki University Central Hospital Laboratory (HUSLAB), Helsinki, Finland. The 
emm types, emm subtypes (emm sequence variants), and sequence types (emm 
typing not yet validated by all of the streptococcus reference laboratories) had 
already been determined according to the Centers for Disease Control and 
Prevention (CDC) GAS emm typing protocol (http://www.cdc.gov/ncidod/biotech 
/strep/strepindex.htm).  The strains were either reference strains or clinical 
isolates from throat, skin, or blood of patients (Table 6). One Shot® TOP10 
Chemically Competent  E. coli (Invitrogen) were used for cloning the CFH5-7 DNA 
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sequences while P. pastoris strain X-33 (Invitrogen) was used as the host organism 
for CFH5-7(402Y), CFH5-7(402H) and CFH5-7(402H/420H) protein expressions. The 
microbes were stored at -70˚C in milk glycerol tubes before inoculation to 
appropriate media for growing (Table 6). 
 
S. pyogenes strains were grown at +37°C with 5% CO2 overnight on blood-agar 
plates supplemented with colistin and oxolinic acid and thereafter in Todd-Hewitt 
broth (Table 6) until the optical density (OD600) was between 0.6-0.8. This 
represented the late log phase growth of S. pyogenes in Todd-Hewitt broth as 
determined from 8 h growth of different S. pyogenes strains, where samples were 
taken each hour for OD600 measurement and CFU counting. After OD600=0.8 the 
proportion of viable bacteria was clearly reduced. For the binding assays (study II) 
the bacteria were washed and diluted in PBS or veronal-buffered saline (VBS; 142 
mM NaCl, 4.9 mM Na 5,5-diethylbarbiturate, pH 7.3-7.5) to reach a bacterial 
concentration from 3 × 107 to 1 × 1010. For analysis of the alternative pathway 
activation in plasma using C3a and Bb enzyme immunoassays (EIA) and a C5b-9 
enzyme-linked immunosorbent assay (ELISA) the bacteria were pelleted by 
centrifugation and stored in milk-glycerol solution at -70°C (study III). For the assay 
measuring multiplication of the bacteria in blood, the bacteria were further diluted 
in media and grown until OD600 =0.15 (studies II and III). 
Zymosan A prepared from Saccharomyces cerevisiae (Sigma-Aldrich) was used as a 
positive control for surface deposition of MBL, C5, C5b-9, C3b, and iC3b molecules 
and as a negative control for C1q deposition in study I. For this, 1 % Zymosan A in 
0.15 M NaCl was activated according to manufacturer’s instructions and thereafter 
diluted in a concentration of 100µg/ml (0.01%). In study III 1 mg/ml Zymosan A 
was incubated in normal human serum (NHS) for 60 min at +37°C to obtain a 
serum sample where AP had been fully activated (i.e. 1000 AU/ml). A dilution 
series of Zymosan A-treated NHS was used to prepare the standard curve for the 
C5b-9 ELISA.  
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Table 6. Microbial strains and growth conditions  
Species 
emm type, emm subtype or 
sequence type Study Origin or supplier** 
S. pyogenes* emm11 II,III Rfs NCTC 100068 
S. pyogenes* emm12 II,III Rfs NCTC 100085 
S. pyogenes* emm2 II,III Rfs NCTC 100064 
S. pyogenes* emm28 II,III Rfs ATCC 12962 
S. pyogenes* emm3 II,III Rfs ATCC 12384 
S. pyogenes* emm4 II,III Rfs NCTC 8326 
S. pyogenes* emm5.8193B II,III Rfs NCTC 8193 
S. pyogenes* emm6.2 (+24nt) II,III Rfs ATCC 12348 
S. pyogenes* emm76 (+54nt) II,III Rfs NCTC 12058 
S. pyogenes* emm78 III Rfs NCTC 12056 
S. pyogenes* emm8 II,III Rfs ATCC 12349 
S. pyogenes* emm1 III Spain 1995  
S. pyogenes* emm22 II,III Blood isolate 
S. pyogenes* emm28 II,III Blood isolate 
S. pyogenes* emm53.1 (-39nt) II,III Blood isolate 
S. pyogenes* emm58 II,III Blood isolate 
S. pyogenes* emm68.3 II,III Blood isolate 
S. pyogenes* emm77 II,III Blood isolate 
S. pyogenes* emm87 II,III Blood isolate 
S. pyogenes* emm89 II,III Blood isolate 
S. pyogenes* st369 II,III Blood isolate 
S. pyogenes* emm1.2b II,III AGN skin isolate 
S. pyogenes* emm18.8 II,III AGN skin isolate 
S. pyogenes* emm55 II,III AGN skin isolate 
S. pyogenes* emm74.0 II,III AGN skin isolate 
S. pyogenes* emm89 II,III AGN skin isolate 
S. pyogenes* emm95.0 II,III AGN skin isolate 
S. pyogenes* st212 II,III AGN skin isolate 
S. pyogenes* st221.0 II,III AGN skin isolate 
S. pyogenes* st212.0 II,III AGN skin isolate 
S. pyogenes* st3757.0 II,III AGN skin isolate 
S. pyogenes* st62.0 II,III AGN skin isolate 
S. pyogenes* st6735.0 II,III AGN skin isolate 
S. pyogenes* stG653 III AGN skin isolate 
S. pyogenes* stL1376 II,III AGN skin isolate 
S. pyogenes* emm25.1 III AGN throat isolate 
S. pyogenes* emm71.0 II,III AGN throat isolate 
S. pyogenes* st206.0 II,III AGN throat isolate 
S. pyogenes* n.t. ¶ II Blood isolate 
S. pyogenes* emm10/12 II Blood isolate 
Pichia pastoris# Pichia pastoris X-33 II Invitrogen 
E. coli§ One Shot® TOP10  II Invitrogen 
*growth conditions: +37°C, 5% CO2; either on blood-agar supplemented with colistin and oxolinic acid 
or in Todd-Hewitt broth 
 #growth conditions: +33°C, either on Yeast Peptone Dextrose-agar or in Yeast Peptone Dextrose or in buffered 
minimal methanol media. All supplemented with Zeocin 
§growth conditions: +37°C, either on Luria-Bertani-agar or in Luria-Bertani media. Both supplemented with 
ampicillin 
¶n.t. seven not emm typed clinical isolates 
**Abbreviations: Rfs, reference strain; AGN, acute glomerulonephritis; NCTC, National Collection of Type 
Cultures ; ATCC, American Type Culture Collection 
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3.1.4 Biological samples 
 
The microscopy-based laboratory diagnosis of Loa loa infection in one patient was 
done by diagnostic laboratory personnel at the Unit of Parasitology, University 
Central Hospital Laboratory (HUSLAB), Helsinki, Finland. After the diagnostic 
procedures the remaining venous EDTA (ethylene diamine tetraacetic acid) and 
Heparin anticoagulated blood samples, obtained from the microfilaremic patient, 
were kindly donated for the scientific experiments with the permission from the 
patient. Samples containing live microfilariae were stored on ice for direct protein-
binding assays, immunofluorescence microscopy and iC3b/C3b deposition assays. 
For Western blotting and cofactor assays the samples were frozen and stored at -
130°C (study I). 
Loa loa microfilariae were isolated from venous blood samples using Percoll 
gradient method where the 1:2 diluted blood sample was centrifuged through a 
percoll-sucrose gradient (study I). Within 35 min of centrifugation (400 × g) the live 
microfilariae were collected from the top of the undermost percoll-sucrose layer 
and washed thoroughly with phosphate-buffered saline (PBS). For Western 
blotting assays the microfilariae were subjected to several steps: low pH, washing 
with PBS, elution with reduced Laemmli-buffer, and thereafter further to 
mechanical homogenization on ice using a homogenizer (UniForm homogenizer, 
Jencons). Samples were collected at each step for analysis. The concentration of a 
homogenate from approximately 150 microfilariae (110 µg/ml) was comparable to 
the concentration of Zymosan A that was used as a positive control in study I.   3.1.5 Genotype data 
 
The complete CFH Y402H genotype data of individuals diagnosed for erysipelas, 
non-erysipelas controls, and individuals diagnosed for recurrent tonsillitis were 
kindly provided by Dr. Jaana Syrjänen (Department of Infectious Diseases, Tampere 
University Central Hospital, Finland) and Dr. Jari Suvilehto (Department of 
Bacteriology and Immunology, Haartman Institute, University of Helsinki, Finland 
and Department of Otorhinolaryngology, Lohja Hospital, Helsinki University 
Hospital, Hospital District of Helsinki and Uusimaa, Finland). The studies on the 
erysipelas and tonsillitis patients were approved by the Ethical Review Boards 
(study III). Blood donor control material was obtained from previously published 
data (Seitsonen et al., 2006) with the approval of Prof. Irma Järvelä (Department of 
Medical Genetics, Haartman Institute, University of Helsinki, Finland). 
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3.2 Methods  3.2.1 Immunological experiments  
 
3.2.1.1 Detection of complement proteins by Western blotting (study I) 
Noncovalently bound complement components C1q, MBL and C5 were eluted 
from isolated Loa loa microfilariae and Zymosan A control particles by using low-
pH buffer (0.1M glycine-HCl pH 2.3). Reduced Laemmli-buffer was used to detach 
the fragments of inactivated C4b bound to surface of microfilariae. To detect the 
membrane associated polymerized C9 complexes, C3b, C4b and fragments of 
inactivated C3b or C4b the microfilariae were further homogenized before 
subjecting samples to SDS-PAGE. Also the presence of CFH and C4BP on 
microfilarial surface was analyzed from the homogenate. Diluted NHS and pure 
complement proteins (Table 4) were used as controls for detection of the 
corresponding components on the microfilarial eluate or homogenate. Samples 
were run into 5% or 10% gels or 5-15% gradient gels, followed by transfer of 
proteins to nitrocellulose membranes and blocking the membranes for 1 h with 3% 
skimmed milk in PBS. After washing, membranes were incubated for 17 h at +4°C 
or for 2 h at +22°C with the primary antibodies diluted 1:2000-1:10000. After 
washing for three times with PBS and incubation with 1:10000 diluted HRP-
conjugated secondary antibody, the proteins were detected using the enhanced 
chemiluminescence (ECL) method. 
 
3.2.1.2 Immunofluorescence microscopy (study I) 
Isolated microfilariae were washed with PBS prior to incubation for 1h at +37°C 
with primary antibodies (2 µg/ml). After washing with 0.5% BSA in PBS and 
incubation for 30 min at +37°C with 1:200 diluted Alexa 488-conjugated antibodies 
the microfilariae were further subjected to three washes. Analysis of CFH and C4BP 
binding on microfilariae was performed using Olympus BX50 fluorescence 
microscope. Samples that were incubated only with the secondary antibodies were 
used as background controls. 
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3.2.1.3 Immunofluorescence quantitation (study I) 
To detect C3b and iC3b formation on microbial surfaces approximately 150 
microfilariae, 100 µg/ml Zymosan A, and 0.01% red blood cells in PBS were 
incubated for 1 h at +37°C together with increasing amount of (0%-20%) NHS in 
PBS. Samples were washed twice with PBS containing 0.025% Tween 20, incubated 
with the primary antibody for 1 h at +22°C, washed again and thereafter incubated 
with 1:100 diluted Alexa 488-conjugated secondary antibody for 30 min at +22°C. 
After final washings the pelleted microbes were resuspended in 25% glycerol and 
transferred into 96 well plates. The fluorescence intensity of each sample was 
counted using a 1423 Victor-2 multilabel counter (Wallac, Finland). 
 
3.2.1.4 Measuring AP activation in serum and plasma (study III) 
Thawed samples of bacteria were washed three times with PBS and adjusted to 
OD600=0.6 to obtain 2 × 108 bacteria/ml. The bacteria were pelleted by 
centrifugation and incubated in a Thermomixer (Eppendorf) with 50% NHS diluted 
in ice cold PBS supplemented with 10 mM MgCl2 and 10 mM ethylene glycol 
tetraacetic acid (EGTA) for 30 min at +37°C . Bacteria that were incubated with 
50% NHS in the presence of 10 mM EDTA were used as a negative control. Since 
EDTA prevents complement activation PBS-EDTA mixture was used to evaluate the 
background of AP activity. Complement activity in the samples was stopped by 
adding 15 µl 0.2 M EDTA. The supernatants were separated by centrifugation and 
stored -70°C for EIA and ELISA analysis. Commercial EIA kits (Quidel) were used to 
measure the formation of C3a and Bb in 1:2000 and 1:200 diluted samples, 
respectively. To measure C5b-9 formation 96-well plates were coated with 2 µg/ml 
of α-C9 neoepitope antibody (Table 4) diluted in a high pH coating buffer (0.2 M 
Na2CO3, pH 10.6) for 17 h at +4°C. Wells were blocked for 2 h at +22°C with 0.5% 
BSA in PBS and washed with PBS containing 0.05% Tween 20. Samples were 
diluted 1:400 and added into the wells. The plates were incubated for 2 h at +4°C, 
washed five times, and 1:1000 diluted α-C7 antibody was added followed by 
incubation for 1 h at +22°C. Wells were then washed and incubated with a 
secondary HRP-conjugated antibody for 1 h at +22°C. OPD (o-phenylenediamine) 
tablets (DAKO) were used as a substrate for detection of the HRP-conjugated 
antibodies according to manufacturer’s instructions. Arbitrary units/ml (AU/ml) 
where calculated from a standard curve obtained by activating 1 ml NHS with 1 mg 
Zymosan A for 60 min at +37°C (normalized to 1,000 AU/ml). Absorbances 
obtained using EIA and ELISA assays were determined using Spectramax ELISA 
reader.  
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For analyzing Bb and soluble C5b-9 (SC5b-9) formation in blood, OD600 = 0.15 
grown bacteria were diluted 1:10000 in PBS and incubated in a Thermomixer with 
PBS or 20 µg CFH5-7 for 15 min at +37°C. Thereafter 1.2 ml of Refludan® (Schering 
AG)- anticoagulated blood was added to the tubes for 1 h incubation at +37°C. 
Samples were taken at three time points, the reaction was stopped in the samples 
with 30-50 mM EDTA. Plasma samples were separated by centrifugation and 
stored at -70°C for Bb EIA and C5b-9 ELISA analysis. 
  3.2.2 Microbiological experiments  3.2.2.1 Opsonophagocytosis assays (studies II and III) 
To see the effect of CFH5-7 inhibition on bacterial multiplication in study III the 
bacteria were grown to OD600=1.5 and diluted 1:10000 followed by incubation with 
CFH5-7 or PBS and thereafter mixed with 1.2 ml of blood. Depending on the 
growth rate of the strain in bood (study II) a total of 100-700 CFU of bacteria were 
diluted in broth and mixed with 1.3-1.6 ml fresh anticoagulated blood obtained 
from donors genotyped homozygous for CFH(402Y) or CFH(402H). In another assay 
(study II), the bacteria were either mixed with fresh blood or blood depleted of 
phagocytes, complement, or both. Complement depleted blood was prepared by 
heat-inactivating the separated plasma for 30 min at +56°C that was then re-mixed 
with the blood cells. Depletion of phagocytes from blood was done by first using 
Percoll gradient separation of phagocytes from other blood cells according to 
manufacturer’s instructions (Fluka Biochemica) followed by addition of the washed 
other cells with heat-inactivated or activated plasma. Bacteria (studies II and III) 
were incubated in blood in an orbital rotator for 3 or 5 h at +37°C and samples 
were taken at 4 or 6 time points and mixed with EDTA. The taken volume was 
replaced with corresponding fresh blood at each (study II) or at 60 and 90 min 
(study III) time points. Samples, or their dilutions, were inoculated onto agar 
plates, incubated for 17 h, the CFUs were counted according to the pour plate 
method and the multiplication factors at each time point were calculated. 
 3.2.3 Experiments with radiolabeled proteins 
 
Purified proteins were radiolabeled with Na125I (Perkin Elmer) using the Iodogen 
method (Salacinski et al., 1981). Briefly, glass tubes were pre coated with Iodogen 
(1,3,4,6-tetrachloro-3a,6a-diphenyl-glycoluril) according to manufacturer’s 
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instructions (Thermo Scientific or Sigma). Na125I was then mixed in the Iodogen-
tube with the purified protein in a ratio of 1 mCi/100 µg, respectively. After 10 min 
incubation the mixture was removed to another glass tube and thereafter the non-
bound 125I was separated from bound using PD-10 columns (Amersham 
Biosciences). The specific activities of the labeled proteins used in the assays were 
0.4 × 106 – 88 × 106 cpm/µg. 
 3.2.3.1 Direct 125I-protein binding assays 
For the C3b deposition assay (study II) bacteria were grown to OD600 = 0.6 (2 × 108 
CFU/ml), washed and adjusted to a concentration of 1 × 1010 bacteria/ml in VBS 
containing 0.1% gelatin (GVB). 40% NHS containing 10 mM EGTA, 5 mM MgCl2 
(NHS-MgEGTA) and 200 000 cpm of 125I-C3 was mixed with 4.5 × 10 bacteria/ml. 
Heat-inactivated serum instead of NHS-MgEGTA was used as negative control for 
C3b deposition. Zymosan A instead of bacteria was used as positive control. 
Samples were incubated for 2h at +37°C; reactions were stopped with 10 mM 
EDTA.  
For direct 125I-protein binding assays 3 × 107 bacteria in GVB (study II) or 40-100 
microfilariae in PBS (study I) were incubated with 25 000 cpm of 125I-labeled 
proteins for 30 min at 37°C in a Thermomixer. The bound 125I-labeled proteins 
were separated from free label by centrifuging the samples through GVB (study II) 
or PBS (study I) containing 20% sucrose. Thereafter the tubes were frozen at -70°C 
and the tubes were cut in to two pieces and the pellets and supernatants were 
placed in separate counting tubes. The radioactivities in the tubes were counted 
using a Wallac Microbeta Trilux gamma counter (Perkin Elmer) and the ratios of 
pellet vs. total activities (pellet and supernatant) were calculated.  3.2.3.2 Radioligand assays 
Bacteria grown to OD600 = 0.6 were washed and used for coating of microtiter 
plates with 1.2 × 108 bacteria/well. The plates were incubated at +37°C until the 
wells were dry. Thereafter, the wells were washed and blocked with 3% BSA 
diluted in PBS for 1 h at +37°C and washed again. For the dose dependent 
competition assay (study II), increasing concentrations (5-50 µg/ml) of unlabeled 
competitor proteins were added and the wells were incubated for 15 min at +37°C. 
Thereafter, in all assays (studies II and III) the wells were incubated with 50 000 
cpm of 125I-labeled proteins containing 0.1% BSA diluted in PBS and washed again. 
Wells were dried, separated from each other and the radioactivities were counted 
using a gamma counter. 
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3.2.3.3 Measuring CFH cofactor activity 
Approximately 75 isolated microfilariae diluted in VBS were incubated with 
100 000 cpm of 125I-C3b and 15 µg/ml factor I for 1 h at +37°C (study I). Mixtures 
containing 125I-C3b and factor I or 125I-C3b, factor I and 10 µg/ml CFH were used as 
negative and positive controls, respectively. The samples were run into 10% SDS-
PAGE gels, fixed with 5% acetic acid, dried using Model 583 Gel Dryer (Bio-Rad), 
and detected by autoradiography. 
 
3.3 Statistical data analysis 
 
Standard deviations for results obtained with replicate samples in two or more 
separate assays (studies II and III) were counted using Microsoft Excel software. In 
the assay where immunofluorescence based quantitation of C3b/iC3b deposition 
was measured (study I) the relationship between the surface deposited C3b/iC3b 
and NHS concentration was modeled by using linear regression analysis in 
Microsoft Excel software and the correlation coefficient value (r2) was calculated. 
Student’s t-test in Microsoft Excel software was used to compare means between 
two independent samples in the direct 125I-protein binding assays (studies I-III), 
radioligand binding assays (study II) and the assays with immunofluorescence 
based quantitation of C3b/iC3b deposition (study I). To compare the effect of CFH 
binding on C3b depositions and the role of complement and phagocytes on 
opsonophagocytosis between three different S. pyogenes strains, a multiple 
comparison test between pairs of means was performed (study II). This was done 
by using one-way analysis of variance (ANOVA) and Tukey’s HSD post-test in 
version 15.0 of SPSS for Windows, Analytical Software (IBM®). Dependence 
between complement activation and binding of CFH proteins, and between SC5b-9 
and Bb or C3a production (study III) was measured by using Pearson’s correlation 
in version 15.0 of SPSS for Windows. 
Allele and genotype frequencies were counted according to the Hardy-Weinberg 
equation (study III). Thereafter a χ2 test was performed to compare the observed 
and the expected genotype frequencies within each study population and the 
deviations from the Hardy-Weinberg equilibrium were determined using Microsoft 
Excel software. Genetic associations between the patient and control groups were 
analyzed by Pearson’s χ2 test (study III), and the odds ratio (OR) and its 95% 
confidence interval (CI) of each comparison was calculated using version 15.0 of 
SPSS for Windows. 
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4 RESULTS AND CONCLUSIONS 
 
4.1 Microbial complement evasion by binding of 
complement regulators in vivo (I) 
 
There are several studies showing that microbial complement evasion is mediated 
in vitro via microbial binding of complement regulators CFH and C4BP. Some of 
these have shown that binding of the regulators promotes the bacterial survival by 
interfering with C3b deposition (China et al., 1993), complement mediated lysis 
(Ram et al., 1998b; Ram et al., 2001a), and by improving microbial phagocytosis 
resistance (Horstmann et al., 1988; Berggård et al., 2001). However, these studies 
have been done in vitro. Therefore, by using a blood dwelling microbe, Loa loa, 
that is extremely well adapted to the human host, we were able to study binding 
of complement regulators in vivo (study I).  
Loa loa microfilariae were isolated from patient blood samples. By using Western 
blotting we examined the complement components that had been bound to the 
surface of microfilariae in vivo in the infected patient. The covalently bound 
fragments were examined from the homogenate of microfilariae. We found that 
complement components C1q and MBL were deposited on the surface whereas no 
deposited C5 fragments or MAC components were observed. Some C4 and C3 
derived fragments were found on microfilariae but those fragments were mainly 
inactivated iC3b and iC4b (Figure 1 of study I).  
In these analyses Zymosan A incubated in NHS was used as a positive control. As 
expected, C1q was not found on Zymosan A particles but deposition of terminal 
components were abundant. These findings lead to the conclusion that 
complement activation is initiated on the surface of the blood dwelling 
microfilariae in vivo but is limited thereafter. Next we analyzed the presence of 
complement regulators on the surface of microfilariae in vivo and clearly observed 
CFH and C4BP from the homogenate (Figure 3 of study I). By using 
immunofluorescence microscopy the binding of CFH and C4BP was localized on the 
sheath layer of the microfilariae (Figure 5 of study I). Incubation of the isolated 
microfilariae with 125I-labeled proteins in vitro showed 8 and 18% binding of CFH 
and C4BP when approximately 100 microfilariae were in each sample, respectively 
(Figure 6 of study I).  
We further examined whether the bound CFH was functionally active and whether 
CFH binding by microfilariae was contributing to the limited number of deposited 
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complement components on the microbial surface. This was done by analyzing 
cofactor activity of the surface bound CFH on cleavage of 125I-C3b (Figure 4 of study 
I) and by using a quantitative method for analyzing C3b/iC3b depositions (Figure 2 
of study I). In Western blotting of the cofactor assay we observed that the α´-chain 
of microfilariae incubated 125I-C3b was cleaved by factor I indicating that the 
surface bound CFH was fully active. Furthermore, the deposition of C3b/iC3b on 
microfilariae was limited (when 7-20% NHS was used) but not totally negative 
when compared to red blood cells that were used as a negative control in the 
assay. According to study I, we were able to show that microbial acquisition of 
complement regulators CFH and C4BP occurs in vivo and can cause limited 
complement activation on surface of Loa loa microfilariae.  
 
4.2 Effect of mutation or polymorphism in domain 
seven of CFH on S. pyogenes immune evasion (II)  
 
The first evidence that a polymorphism in domain seven of CFH has functional 
consequences was found in 2005 when four separate studies showed association 
between CFH Y402H polymorphism and AMD (Edwards et al., 2005; Hageman et 
al., 2005; Haines et al., 2005; Klein et al., 2005). This was an interesting finding 
since the domain where the substitution is located has been shown to mediate the 
binding of CFH to M protein of S. pyogenes (Blackmore et al., 1998a; Giannakis et 
al., 2003). It has also been assumed that some genetic factors such as 
polymorphisms in TLR-4 (Liadaki et al., 2011) and Ficolin-2 (Messias-Reason et al., 
2009) genes could affect the susceptibility of some individuals to S. pyogenes 
infections.  
We hypothesized that if the binding between CFH and M protein is mediated via 
residues close to the polymorphic site in domain seven the substitution changing 
the charge of the site could also change the affinity of the interaction. In study I we 
had found that CFH binding on the microbial surface occurs in vivo and therefore 
we assumed that impaired binding of CFH on S. pyogenes could also have 
functional consequences and thereby influence infection susceptibility.  
Before analyzing the impact of the CFH Y402H polymorphism on microbial evasion, 
we studied binding of CFH on several S. pyogenes strains (Figure 13). On the basis 
of these results, we chose three S. pyogenes strains with different binding affinity 
to 125I-labeled CFH to study complement activation by the bacterium. By incubating 
these strains with NHS and a trace amount of 125I-C3 we saw that the more the 
strain bound 125I-CFH the less C3b opsonization was detected (Figure 1 of study II). 
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When the same strains were incubated in full blood the same trend in bacterial 
multiplication was seen. The strain that bound CFH efficiently (st369) multiplied 
well in the presence of complement and phagocytes while the multiplication of an 
intermediate CFH binding strain (emm5) was slower. The strain that did not bind 
CFH (emm8) did not survive in the presence of complement and phagocytes. As a 
control assay it was determined that this strain survived well when complement 
and phagocytes were absent. When only complement was absent the emm8 strain 
survived but, surprisingly, when only phagocytes were absent the bacteria failed to 
survive. This was interesting since the data showed not only that restriction of 
complement activation can lead to survival of the CFH binding bacteria but also 
that complement could directly limit survival of a non-CFH binding gram-positive 
bacterium – a property thought to be restricted to gram-negative bacteria.  
 
 Figure 13. Binding of CFH from serum to 20 S. pyogenes strains. A serum bathing assay was performed to show the differential binding of CFH to several S. pyogenes emm types . Bacteria were incubated for 30 min in 20% normal human serum (pool from six individuals) and washed three times with PBS. The bound proteins were eluted using 0.1M glycine-HCl (pH 2.3) and detected by Western blotting as in study I where CFH was detected from the surface of Loa loa.  
 
To study the effect of the Y402H polymorphism on complement evasion of S. 
pyogenes full length CFH proteins CFH(402Y) and CFH(402H) were isolated from 
individuals homozygous for the corresponding allele. Binding of these proteins to 
the same S. pyogenes strains was examined by direct 125I-protein binding assays 
and radioligand assays (Figure 5 of study II). These data showed that the binding of 
CFH(402H) protein was clearly impaired when compared to the corresponding 
CFH(402Y) proteins.  
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The binding of CFH on S. pyogenes was also studied by using recombinant 
constructs CFH5-7(402Y), CFH5-7(402H), and CFH5-7(402H/420H). The proteins 
consisted of CFH domains five to seven (CFH5-7). The reason for generating three 
constructs was that the intended 402H mutation in the original publication (study 
II) was accidentally generated at position 420Y in the DNA template that already 
contained histidine (H) at position 402. As explained in the corrigendum to the 
article II, instead of using numbering from the preprotein (with 18 aminoacid signal 
sequence) we used numbering from the beginning of the mature protein. Later it 
was noticed that the specific polymorphism in the AMD association studies had 
been located starting from the signal sequence at position Y402H or SNP T1277C 
(rs1061170) that was position Y384H in the expressed protein (Clark et al., 2006). 
Therefore, the results in the study II have been obtained with CFH5-7 fragments 
CFH5-7(402H) - thought to be CFH5-7(402Y) - and CFH5-7(402H/420H) - thought to 
be CFH5-7(402H). In contrast, the results in the corrigendum to the article II were 
obtained using the fragments CFH5-7(402Y) and CFH5-7(402H) (Figure 14).             Figure 14. Silver staining of recombinant proteins CFH5-7(402Y) and CFH5-7(402H). The purified proteins were separated by SDS-PAGE and stained with Silver stain. Molecular weight standard can be seen at the left side of the figure. The CFH5-7(402Y) or CFH5-7(402H) proteins can be seen as 21 kDa bands 
 
We examined binding of the recombinant constructs to several different S. 
pyogenes strains. In the study II the majority of the strains showed decreased 
binding of CFH5-7(402H/420H) compared to CFH5-7(402H) (Study II). When both 
the direct binding and radioligand binding assays were done with the CFH5-7(402Y) 
and CFH5-7(402H) fragments (Figure 15), fewer strains showed decreased binding 
of the CFH5-7(402H) compared to the CFH5-7(402Y) (corrigendum to study II).  
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 Figure 15. Binding of CFH5-7(402Y) and CFH5-7(402H) to S. pyogenes strains using direct binding assay (A) and radioligand assay (B). This data is the basis for the correction to fig. 6 of the article II. The strains are shown in ascending order based on the binding percentage of the CFH5-7(402Y) but have been separated into three categories by the vertical line depending on the statistically significant difference between binding of the CFH5-7(402Y) and CFH5-7(402H) recombinant fragments. The horizontal dashed line indicates the level of binding by the negative control strain emm8. Strain st369 is used as a positive control. Mean ±SD of triplicate samples in a representative of two individual experiments is shown. Cpm, counts per minute; nt, not typeable. 
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When the strains were categorized depending on the statistically significant 
difference between binding of the CFH5-7(402Y) and CFH5-7(402H) three groups 
were indentified: those strains that showed no difference, those with reduced 
binding to the CFH5-7(402H) and those with reduced binding of the CFH5-7(402Y). 
However, the results of only three strains (from which one was negative control 
strain emm8) of the latter group could be repeated in both direct binding and 
radioligand assays. In a competition assay, however, binding of 125I-CFH5-7(402Y) 
on strain st369 was more decreased when incubated with CFH5-7(402Y) compared 
to the incubation with CFH5-7(402H) (Figure 16). According to these results, it is 
clear that several of the tested S. pyogenes strains bind CFH via domain seven in 
such a way that the residue where Y402H substitution is located is associated with 
CFH binding. Moreover, binding of CFH onto most of the strains is strongly affected 
by the Y420H substitution.  
 
   Figure 16. Dose-dependent inhibition of binding of 125I-CFH5-7(402Y) to the GAS strain st369 by CFH5-7(402Y) or CFH5-7(402H). CFH5-7(402Y) or CFH5-7(402H) were added before addition of the 125I-CFH5-7(402Y) protein in a radioligand assay. Percentage of bound radioactivity is shown as relative to the maximal CFH5-7(402Y) binding without the inhibitor. Mean ±SD of triplicate samples in one individual experiment is shown. 
 
To see whether the reduced binding of CFH(402H) compared to the binding of 
CFH(402Y) on bacterial surface affects bacterial survival in human blood we 
incubated three strains (emm5, emm8 and st369) in blood obtained from 
individuals homozygous for either CFH(402Y) or CFH(402H). When the 
multiplication factors were calculated we found that within five hours of 
incubation the bacterial survival was significantly reduced in the blood obtained 
from the CFH(402H) homozygous individuals compared to the blood from 
CFH(402Y) individuals (Figure 7 of study II). Our main conclusion in the study II was 
that CFH Y402H polymorphism clearly affects binding of CFH to S. pyogenes surface 
in such a way that it has an impact in bacterial survival in blood ex vivo. 
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4.3 Multiplication of S. pyogenes bacteria in blood 
ex vivo can be impaired by inhibiting CFH binding 
with CFH5-7 (III) 
 
In study II we had shown that CFH binding by S. pyogenes clearly reduces bacterial 
C3b opsonization and opsonophagocytosis. Since the interaction between CFH and 
M protein is mediated via the amino-terminal HVR of M protein (Johnsson et al., 
1998), the region responsible for the emm type of the strain, we wanted to study 
this phenomenon using several strains of different emm types.  
 
 Figure 17. Inhibition of CFH binding to S. pyogenes M protein by CFH5-7. Recombinant CFH5-7 that does not act as a complement regulator but binds to M protein was used for competing with CFH in binding to S. pyogenes surface.  
 
By incubating 38 different S. pyogenes strains (Study III) with NHS where only AP 
was active and by detecting AP activation markers from the supernatants we found 
that CFH binding as well as binding of CFH construct with only domains 5-7 is 
clearly negatively correlated with release of C3a fragment and generation and 
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release of SC5b-9 (Figures 1 and 2 of study III). In a whole blood incubation assay 
we reviewed the phenomenon in an opposite perspective. The binding of CFH was 
inhibited using a non-functional CFH5-7 fragment prior to inoculating the bacteria 
in whole blood. We hypothesized that the fragment lacking the cofactor active site 
1-4 could bind competitively on the bacterial surface thus preventing bacterial 
immune evasion via CFH binding (Figure 17). When the activation markers Bb and 
SC5b-9 were analyzed from the supernatants we observed that complement 
activation was clearly enhanced when the bacteria were incubated in the presence 
vs. absence of CFH5-7 (Figure 4 of study III). CFH5-7 did not cause an increase in 
the level of the activation markers when the bacteria were absent, showing that 
the recombinant fragment did not cause excess complement activity in blood ex 
vivo. When four S. pyogenes strains were subjected to a multiplication assay they 
all multiplied well in the absence of CFH5-7 but failed to do so when CFH5-7 was 
present (Figure 5 of study III). All these findings were consistent with our 
hypothesis that binding of CFH via the domain seven is crucial for survival of S. 
pyogenes in blood. 
 
4.4 Association of CFH Y402H polymorphism with 
S. pyogenes infections (III) 
 
It was clear on the basis of our previous results that the CFH(402H) allotype has 
diminished binding to certain S. pyogenes strains compared to the binding of 
CFH(402Y). Since the decreased binding reduces bacterial survival in vitro we 
hypothesized that CFH(402H) homozygosity could be a protective phenotype 
against S. pyogenes infections. To test this we performed a genetic association 
study where individuals suffering from streptococcal infections were genotyped 
for the single nucleotide polymorphism T1277C in the CFH coding allele 
responsible for the CFH Y402H polymorphism. The patient data consisted of 
genotype data of individuals suffering from recurrent streptococcal tonsillitis 
(n=209) or erysipelas (n=278). Genetic data of non-erysipelas control patients 
(n=105) and healthy blood-donors (n=305) were used as controls.  
When the allele genotype frequencies were compared between the patient and 
control groups we observed that the frequencies of C alleles and CC genotypes 
were significantly lower in the combined patient group than in the non-erysipelas 
or combined control group. On the basis of these results it seems that the Y402H 
polymorphism in CFH is associated with streptococcal tonsillitis and erysipelas, 
infections that both are mainly caused by S. pyogenes.  
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5 DISCUSSION  
 
5.1 In vivo binding of complement regulators 
 
Microbial CFH binding has been shown to be an important complement evasion 
mechanism for several pathogens in vitro. Before the studies presented in this 
thesis there was no evidence, however, of acquisition of CFH in human infection in 
vivo. It has been difficult to test this since good animal models are not available 
due to the species specificity of CFH binding as demonstrated for pathogens such 
as S. pneumoniae and N. meningitidis (Lu et al., 2008; Ngampasutadol et al., 2008). 
However, there is evidence that preincubation of Streptococcus pneumoniae with 
human CFH increases streptococcal survival (Quin et al., 2005) and enhances 
bacterial invasion in vivo in a mouse model (Quin et al., 2007).  
It has been suggested that during loiasis high level of anti-filarial IgG has an 
important role in controlling the microfilaremia (Akue et al., 1997) with the help of 
CP of complement. Together they mediate antibody dependent neutrophil 
adherence to the microfilariae (Pinder et al., 1992). Since in study I we observed 
complement regulatory proteins C4BP and CFH on the surface of the isolated 
microfilariae it is likely, however, that opsonization and thereby neutrophil 
adherence could be restricted on the microfilariae in human blood in vivo.  
In an earlier study where binding of CFH on Onchocerca volvulus microfilariae has 
been demonstrated (Meri et al., 2002) the main role of the surface bound 
complement regulators was suggested to be the prevention of the action of 
neutrophils, not the direct lysis of complement. The reason for this is the existence 
of the thick cuticle on microfilariae surface that is obviously resistant to the 
cytolytic effects of complement. The opsonins C3b and iC3b can further be 
inactivated to C3dg by CR1 in the presence of factor I providing a ligand for CR2 of 
B-cells thereby decreasing the threshold for B-cell activation (Morgan et al., 2005). 
Therefore, reduced formation of C3b and iC3b on microfilariae observed in study I 
could potentially also delay antifilarilal antibody production and thereby affect 
longevity of microfilariae in patients (Akue et al., 1997). CFH binds to the 
outermost sheath layer of the microfilariae (study I) but the specific CFH 
interacting ligand is not yet known. It also remains to be tested by using 
recombinant fragments of CFH which are the domains in CFH mediating the 
binding on Loa loa microfilariae.  
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5.2 CFH binding within S. pyogenes strains 
 
In this thesis and in earlier studies where CFH interaction with clinical isolates has 
been studied (Horstmann et al., 1988; Perez-Caballero et al., 2000; Suvilehto et al., 
2008) a total of 35 S. pyogenes strains have been found to bind CFH (Table 7). The 
level of CFH binding to the bacteria, however, varies between the strains. As 
demonstrated in the study II it seems that CFH binding by S. pyogenes is mainly 
mediated via domains 5-7 (19 of 35 CFH binding strains). It was found  that certain 
strains only bound CFH5-7 but not CFH. This could be explained by the folded 
structure of CFH (DiScipio, 1992b) where the M protein-binding site is less easily 
exposed when compared to the truncated molecule CFH5-7. This could also be the 
reason why in certain cases S. pyogenes binds CFHL-1 rather than CFH (Perez-
Caballero et al., 2000).  
As suggested by others (Perez-Caballero et al., 2000; Suvilehto et al., 2008) there is 
also variability in CFH binding between different isolates within the same emm 
type. In our hands the two different isolates of emm28 strains, that according to 
the sequence data share 100% similar emm sequences, showed completely 
different CFH binding: the blood isolate bound CFH clearly while the reference 
strain bound CFH very weakly (Table 7). It is important to note that CFH binding 
correlated with the complement activity caused by the bacterium indicating that 
CFH binding is important in complement evasion of S. pyogenes. Therefore, 
although the emm type can be determined at the genetic level it is still unclear 
whether the diminished CFH binding is due to the lack of interaction between CFH 
and surface bound M protein or due to the lack of M protein expression by the 
isolate because of, for example, phase variation. When incubated in culture media 
S. pyogenes undergoes phase variation during the stationary growth phase. Here 
the expression of the emm and speB genes are significantly reduced while the 
expression level of slo is unaffected changing the bacterium almost completely 
sensitive to phagocytosis (Leonard et al., 1998). Therefore, in this study bacteria 
were grown to log phase before subjecting to CFH binding assays. Since in some 
studies (Perez-Caballero et al., 2000; Suvilehto et al., 2008) CFH binding has been 
analyzed using bacteria grown for 18 h this could at least partly explain why CFH 
binding of different isolates of the same emm type differs between studies. It is 
also possible that CFH binding is reduced due to the action of bacterial proteases 
on the M protein or due to the spontaneous release of the M protein from the 
bacterial surface (Åkesson et al., 1994) or even due to small changes in M protein 
sequences that spontaneously occurs in the HVR part of the M protein.  
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Table 7. Formation of C3a and binding of CFH/CFH5-7 on S. pyogenes 
 
 Study III 
 
      Study II and III 
 
Previous studies 
 
 
    
Strain C3a CFH CFH5-7 CFH#,§ 
st212 - +++ +++  
emm1.2b - +++ +++  
st6735.0 - +++ +++  
emm71.0 - +++ +++  
st369 + ++ +++  
st212.0 - ++ +++  
emm89 + ++ +++  
emm11*,# - + +++ + 
emm28*,§ + + +++ + 
emm87 - + +++  
emm95.0 - +++ ++  
st62.0 + +++ ++  
st3757.0 ++ +++ ++  
emm18.8# - ++ ++ + 
emm2 + ++ ++  
st206.0 ++ +++ +  
emm25.1 ++ +++ +  
st221.0 - +++ _  
stG653 - +++ _  
emm74.0 - ++ +  
emm53 + _ ++  
emm22 ++ _ ++  
emm68 ++ _ ++  
emm77 +++ _ ++  
emm55 - ++ _  
emm6#,§ + ++ _ + 
emm5+ +++ ++ _ + 
emm3 +++ ++ _ _ 
emm58 +++ + +  
emm1*# - _ + + 
emm76  - _ +  
emm28*,§ +++ - + + 
emm12 ++ + _ _ 
emm78 +++ + _  
stL1376 +++ + _  
emm4*# +++ _ _ + 
emm8*# +++ _ _ + 
emm19§ n.a. n.a. n.a. + 
emm24#,§ n.a. n.a. n.a. + 
emm29*# n.a. n.a. n.a. + 
emm30*# n.a. n.a. n.a. + 
emm31*# n.a. n.a. n.a. + 
* Differences in CFH binding between isolates; na, not assayed 
CFH binding shown in Reference: #Perez-Caballero et al., 2000, §Horstmann et al., 1988  
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5.3 CFH binding and S. pyogenes survival 
 
Binding of CFH to different S. pyogenes strains shows a high variability – some 
strains bind CFH efficiently while others completely lack the ability. The amount of 
detected CFH binding to the different S. pyogenes strains shows a negative 
correlation with the level of complement activation induced by the bacteria. In 
addition, CFH binding correlates positively with bacterial survival in blood. This 
indicates that M protein expression level and thereby the amount of CFH bound on 
S. pyogenes surface and/or the affinity between CFH and M protein determines 
the efficacy of complement evasion. It seems that CFH binding may play a key role 
in the streptococcal survival in serum or blood at least in vitro. The importance of 
complement system in elimination of S. pyogenes and the function of CFH in 
bacterial survival can be demonstrated in an ex vivo survival model (study II) where 
depletion of complement allows growth of a non-CFH binding strain that does not 
survive in fresh blood. Interestingly, the presence of complement in the absence of 
phagocytes can be enough to decrease survival of a non-CFH binding strain 
indicating that complement somehow acts on this gram-positive bacterium by 
itself. The mechanism behind this novel observation is unknown. It remains to be 
studied if excessive amount of C3b deposits could interfere with, for example, 
bacterial metabolism or cell division. 
Although the domains 5-7 are mainly mediating the binding of CFH on S. pyogenes 
surface it is evident that some strains interact with other domains in CFH using 
ligands other than the M protein. For example, the binding of CFH to M6 protein 
has been localized to CFH domain seven (Blackmore et al., 1998a) but in our hands 
the emm6.2 isolate bound CFH5-7 only weakly when compared to the negative 
control strain emm8. This isolate differed slightly from the emm6 CDC strain 
(90.4% sequence identity) in the emm sequence that could possibly explain the 
impaired binding of CFH5-7. Nevertheless, the isolate bound clearly the whole CFH 
protein indicating that the interaction is mediated via two ligands, probably also 
via Scl1, that has been shown to bind CFH via domains 18-20 (Caswell et al., 2008; 
Reuter et al., 2010). Because the emm6.2 strain showed only limited complement 
activation in serum when compared to the negative control strain emm8, the 
binding of CFH outside domains 5-7 could be an alternative method to evade 
complement attack. Binding of CFH via domain seven is, however, probably more 
common within S. pyogenes bacteria because Scl1, that has been shown to bind 
CFH via domains 19-20, is also expressed by strains emm1, emm28, emm4, 
emm77, emm12 and emm2 that do not interact with CFH (Caswell et al., 2008). It 
could also be that binding of CFH via domains 5-7 leads to more efficient 
complement evasion than binding of CFH via other domains. The results showing 
that the S. pyogenes emm6 mutant lacking M6 protein becomes sensitive to 
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complement and phagocytosis indicate that expression of M6 protein is important 
for immune evasion (Horstmann et al., 1988). In addition, introduction of the 
emm6 gene to an M protein deficient strain restores its ability to resist 
phagocytosis (Perez-Casal et al., 1992). 
It is possible that the CFH-binding region within the different M proteins is variable 
since the interaction site has been localized to two distinct areas: the C-repeat 
region for the M6 protein (Fischetti et al., 1995; Perez-Casal et al., 1995) and HVR 
for M5 and probably also for M6 (Johnsson et al., 1998; Kotarsky et al., 2001). 
These differences are not surprising since size variation found in A and B repeat 
regions between different M proteins also occurs within M6 expressing laboratory 
isolates (Fischetti, 1989). As previously mentioned, the CFH binding does not 
necessarily lead to complement and phagocytosis resistance especially if the 
binding affinity or the amount of expressed ligand is not sufficient. For example, in 
study III the emm5 strain binds some CFH but does not diminish complement 
activity in human serum. Furthermore, some phagocytosis resistance by the strain 
can be seen when compared to a non-CFH binding strain but the multiplication in 
blood is fairly limited when compared to strains showing high level CFH binding. 
Therefore, it is likely that CFH binding does not completely explain the limited 
phagocytosis resistance of this particular strain. Although the CFH binding by the 
M5 protein has been reported to occur via HVR it looks like the B-repeat region is 
essential for phagocytosis resistance of an emm5 strain studied by others (Kotarsky 
et al., 2001; Sandin et al., 2006). It is, however, noteworthy that while the deletion 
of the B-repeat region of the M5 protein almost completely abolished bacterial 
phagocytosis resistance the partial deletion of the HVR clearly decreases the 
resistance (Sandin et al., 2006) indicating that CFH binding is partially involved in 
the phenomenon. The deletions done in the M protein could also partially destroy 
the coiled coil structure of the protein or shorten the protein to the extent that it 
has an influence on the studied interactions. 
Certain M proteins bind CFHL-1 (Johnsson et al., 1998) and none of the assays in 
this thesis ruled out this possibility. On the contrary, there was one strain (emm87) 
that showed weaker binding of both 125I-labeled CFH (Table 7) and CFH from serum 
(Figure 13) when compared to the binding of CFH5-7.  CFH and CFHL-1 are identical 
in the structure of the first seven domains, except of four additional amino acids in 
the carboxyl-terminal end of CFHL-1, whose function is unknown. They are 
encoded by the same gene and both have cofactor activity in the four most amino-
terminal domains. Because of the structural similarities it is probable that CFH and 
CFHL-1 share similar functions in S. pyogenes complement evasion. However, since 
the serum concentration of CFHL-1 is 10-50 times lower than the concentration of 
CFH it is possible that the importance of CFHL-1 binding by the bacterium is more 
relevant in specific locations in human body (Zipfel and Skerka, 1999).  
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Taking together, the high variability in CFH binding within different S. pyogenes 
strains can be explained by the binding affinity of CFH to the expressed M protein, 
the expression level of the M protein e.g. due to the limited expression in certain 
growth phase of S. pyogenes, alternative ligands for CFH binding, or inability of full 
CFH but not CFHL-1 or CFH5-7 to bind to M protein. Nevertheless, CFH binding by 
the microbe is most likely the main phenomenon that determines bacterial 
complement evasion and survival in vitro and therefore can be generalized as a 
common property for the studied species.  
 
5.4 The interaction between CFH and M protein 
 
The present knowledge on the interactions between S. pyogenes and CFH is mainly 
based on studies done using clinical S. pyogenes isolates or single M proteins. 
Therefore we cannot claim that M protein is the definitive ligand mediating CFH 
binding by most S. pyogenes strains. Since CFH5-7 mediates binding to most S. 
pyogenes strains (studies II and III) it is likely that these strains use these domains 
to bind CFH via M protein. In addition, the high variability in HVR of M protein 
between different strains gives the best explanation for the differences in CFH 
binding observed within these strains.  
At the protein level, the main residues in CFH domain seven interacting with the M 
protein are at least 387R-388K, 404R-405K (Giannakis et al., 2003), and 402Y as 
suggested by the study II. Also, a Y to H substitution in residue 420, obtained as a 
result of accidental misnumbering as explained in Materials and Methods, resulted 
in significant decrease in CFH5-7 binding suggesting that this residue is also 
important for the interaction. All the experiments were done with the three CFH5-
7 fragments, CFH5-7(402Y), CFH5-7(402H), and CFH5-7(402H/420H). The main 
message and the conclusions obtained with with CFH5-7(402Y) and CFH5-7(402H) 
(corrigendum to study II) were the same as those obtained with CFH5-7(402Y) and 
CFH(402Y/420H) and full length CFH from CFH(402Y) and CFH(402H) homozygous 
individuals (study II). This is logical since the residue 420 is located at the same side 
of the domain as the polymorphic site 402 and the residue 405 previously shown 
to be involved in binding to M6 protein (Figure 18) (Giannakis et al., 2003; Prosser 
et al., 2007). Furthermore, the mutation to the residue 420 gave additional 
information about the site of CFH responsible for binding to M proteins. This is 
important since the residue 420 seems to be the most widely used residue in 
binding of CFH5-7 to various M proteins and could thereby become a main target 
for therapeutic approach in preventing S. pyogenes immune evasion in future. 
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 Figure 18. A schematic presentation of simultaneous binding of CFH to C3b and S. pyogenes M protein. According to the combined mutagenesis data including the data in study II the residues 388, 402, 405 and 420 are all involved in M protein binding. The residues are marked in the crystal structure of domains 6-8 (Prosser et al., 2007) (PDB entry 2UWN). The same domains are marked in gray in the schematic presentation of simultaneous binding of surface bound C3b, CFH, and S. pyogenes M protein. 
 
Although the key results in the corrigendum are similar to those in the original 
published article (study II) the binding of the CFH5-7(402Y) and CFH(402H) 
constructs to more than 40 GAS strains showed some differences compared to the 
binding of CFH5-7(402H) and CFH5-7(402H/420H). Most of the strains showed 
impaired binding of the CFH5-7(402H) compared to the CFH5-7(402Y) recombinant 
fragment as expected. However, two of the strains showed the opposite results. 
This indicates that the residues mediating the interaction between CFH and GAS M 
protein are less conserved within different GAS strains than what we originally 
expected. However, the residue 420 could be important in several CFH-M protein 
interactions. The interaction between S. pyogenes M protein and the domain 
seven of CFH is mediated by multiple residues. When observing the location of the 
known streptococcal binding residues 402, 405 and 420 in the crystal structure of 
the CFH domains 6-8 (Prosser et al., 2007)  it appears that the binding site follows 
the domain seven longitudinally. This kind of binding may allow simultaneous 
binding of the regulatory active domains 1-4 of CFH to C3b as represented in (Wu 
et al., 2009). Using the obtained information, the next aim could be to try to obtain 
the X-ray crystal structure of the CFH5-7:M protein complex in the future using 
also M proteins expressed by other emm types than emm5 and emm6. 
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5.5 CFH Y402H polymorphism and susceptibility 
to streptococcal infections 
  
Certain polymorphic variants in CFH gene have been found to be associated with 
increased risk of developing diseases such as aHUS, MPGNII, or AMD. There is also 
evidence that variation in CFH gene is associated with a risk to develop invasive N. 
meningitidis infections (Davila et al., 2010). This is interesting since the 
complement resistance of N. meningitidis is mediated via binding of CFH using the 
surface proteins Fhbp (Madico et al., 2006) and NspA (Lewis et al., 2010). Both of 
these ligands bind CFH via domain seven – the same domain that mediates the 
interaction between CFH and S. pyogenes M protein. In studies where the role of 
CFH binding by N. meningitidis has been studied show that the presence of CFH in 
vivo improves the ability of N. meningitidis to cause bacteremia in infant rats (Vu 
et al., 2012) and that increased concentrations of CFH in plasma, caused by C496T 
homozygocity in the CFH coding gene, is associated with increased risk of 
developing N. meningitidis infections (Haralambous et al., 2006).  
In this thesis we show (study II), by comparing the binding of allotypes CFH(402Y) 
and CFH(402H) to S. pyogenes strains, that the decreased binding of CFH in the 
presence of only the CFH(402H) allotype, also leads to functional consequences. 
Here, bacteria induced complement activation is enhanced and multiplication of 
the bacteria is decreased (Figure 19) indicating that host genetic variation in CFH 
affects survival of S. pyogenes. This is also supported by the genetic association 
study (study III) where Y402H polymorphism (C1277T) suggests an association with 
streptococcal diseases. Therefore CFH Y402H polymorphism could be important in 
determining the susceptibility of an individual to streptococcal diseases and could 
also explain why the AMD associated allele is enriched in human population 
despite of its harmful effect later in life.  
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 Figure 19. A hypothetical presentation of the effect of different binding properties of CFH(402Y) and CFH(402H) allotypes on survival of S. pyogenes. The bacterium binds allotype CFH(402Y) (dark grey) on its surface and thereby evades complement attack and survives in blood. The binding of the allotype CFH(402H) (light grey) on M protein is reduced interfering with S. 
pyogenes immune evasion and leading to decreased bacterial survival. The domain seven containing the polymorphic Y402H site is marked in white. 
 
Whether the Y402H polymorphism could affect host susceptibility to other 
infections caused by a CFH domain seven binding bacterium is not yet known. A 
genome wide association study (GWAS) (Davila et al., 2010), however, suggests 
only very nominal association of the polymorphism to N. meningitidis infections. In 
this study, it is possible that the true disease variant has been lost in the statistical 
noise when multiple variants have been examined simultaneously. Although the 
study in this thesis showed only a possible association of the Y402H polymorphism 
in S. pyogenes infections the observed association was strongly supported by the 
functional studies where the Y402H polymorphism was shown to affect survival of 
S. pyogenes in blood.  
It would be interesting to study the association of Y402H polymorphism in S. 
pyogenes diseases by using data of patients with verified S. pyogenes infections 
since erysipelas can be caused by other risk factors than the variation in CFH such 
as edema, broken skin and obesity (Karppelin et al., 2010). In addition, the 
infection can also be caused by group G streptococcus since it has often been 
isolated from erysipelas patients (Siljander et al., 2008). It is also possible that the 
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majority of the S. pyogenes emm types isolated from Finnish erysipelas and 
tonsillitis patients do not bind CFH via the domain seven. In invasive S. pyogenes 
cases the emm types 28, 1, 84, 75 and 89 are predominant but in the study II no 
CFH binding was detected to the used emm1 strain representing the most 
common emm type isolated in Finland in 2007 (Siljander et al., 2010). Within 
strains isolated from Finnish tonsillitis patients emm28 is probably the most 
common (Suvilehto et al., 2008). The results on CFH binding by two different 
isolates of type emm28 (study III) showed evidence that there are variation in CFH 
binding even within the same emm type. From the two emm28 strains, the 
reference strain did not bind CFH while the blood isolate bound CFH indicating that 
a spontaneous mutation in the M protein, or a decrease in M protein expression 
level of the reference strain had occurred. There is at least evidence that S. 
pyogenes bacteria isolated from asymptomatic patients can show limited M 
protein expression because of the phase variation (Leonard et al., 1998).  
In future studies, it could be beneficial to collect data from patients with invasive S. 
pyogenes infections and study the association of Y402H polymorphism in S. 
pyogenes infections using additional control material where the S. pyogenes 
infection has been excluded. Furthermore, the effect of Y402H polymorphism in 
infections caused by CFH binding Loa loa microfilariae should be studied although 
the interacting domains in the protein are not known (study I). Previous studies 
have suggested that genetic factors may play a major role in susceptibility or 
resistance to Loa loa infections. These could partly explain why the prevalence of 
loiasis in hyperendemic regions rarely exceed 30% although these individuals are 
continually exposed to the parasite (Garcia et al., 1999).  
 
5.6 CFH5-7: a drug candidate against S. pyogenes 
infections? 
 
S. pyogenes is a common pathogen affecting individuals around the world and 
many of the infections may lead to harmful sequelae or complications and 
lethality. A lot of effort in prevention of S. pyogenes infections has been focused 
on generating M protein vaccines, which could be the most promising vaccine 
candidates, particularly targeted against the rheumatogenic strains. It is, however, 
well known that e.g. arthritis following S. pyogenes infection is based on an 
autoimmune reaction where M protein has been shown to induce production of 
antibodies against host tissues. This indicates that molecular mimicry between M 
protein and human proteins could play a role in the pathogenesis of this disorder 
(Dale and Beachey, 1985; Cunningham et al., 1997). This is further supported by 
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the finding that both Coxsackie B3 virus and S. pyogenes infections can induce 
autoimmunity leading to heart diseases and their proteins, VP1 and M protein, 
share similarities and cross reactivity with heart tissues (Cunningham et al., 1992). 
Although most M protein vaccine trials have shown production of protective 
antibodies and good tolerance among vaccinated individuals the safety of the 
vaccine candidate must be thoroughly analyzed (Steer et al., 2009). The possible 
induction of an autoimmune disorder by a vaccine is a major concern especially 
because of a possible long latency period. For example the interval between S. 
pyogenes infection and onset of post-streptococcal glomerulonephritis, rheumatic 
fever, or narcolepsy are 1-2 weeks, 3-8 weeks, and weeks to months, respectively 
(Aran et al., 2009).  
CFH5-7 is a fragment of human CFH lacking the regulatory site but simultaneously 
being able to bind to several S. pyogenes emm types. Binding of the CFH5-7 
fragment to several S. pyogenes strains significantly increases the complement 
activity against S. pyogenes bacteria (study III) that in turn increases the 
phagocytosis of the pathogen. When added in fresh human plasma the CFH5-7 
fragment does not cause excess complement activation by itself. In contrast to M 
protein vaccine candidates, human CFH5-7 fragment is unlikely to be antigenic and 
therefore most probably does not induce autoimmunity. By preincubating S. 
pyogenes bacteria with CFH5-7 the binding of whole CFH is inhibited (study III). 
Two major findings shown in this thesis indicate that this inhibitory effect of CFH5-
7 on CFH binding to S. pyogenes could also affect to the survival of the bacterium. 
First, those strains that bind CFH5-7 show increase in AP activation. Second, CFH 
binding by S. pyogenes is associated with rapid multiplication rate of the bacteria 
in blood while the multiplication rate decreases when the bacteria are 
preincubated with CFH5-7 (study III).  
The CFH5-7 fragment could interfere with CFH binding not only to M protein but 
also to Fba on S. pyogenes. The reason for this assumption is that Fba binds CFHL-1 
indicating that the interaction could be mediated via domains 5-7 of CFH 
(Pandiripally et al., 2002; Birkenfeld et al., 2011). Since at least three CFH 
interacting ligands have been found on S. pyogenes it is also probable that within 
some strains the efficient phagocytosis resistance requires two or more CFH 
ligands. In this case binding of CFH5-7 fragment to M protein or Fba could be 
enough to interfere with CFH binding to the extent that the bacteria become 
sensitive to phagocytosis.  
It has been proposed that bacterial invasion of host cells could explain the 
recurrence of S. pyogenes infections (such as tonsillitis and erysipelas) as well as 
failures in bacterial eradication, since intracellular bacteria could avoid the effects 
of penicillin (Österlund et al., 1997). The recurrence of S. pyogenes infections has 
also been suggested to be caused by β-lactamase producing commensal bacteria in 
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oral flora (Brook, 1984). Since S. pyogenes Fba that also interacts with CFH has 
been shown to promote microbial entry into host cells (Terao et al., 2001) the 
CFH5-7 fragment might also interfere with bacterial invasion into epithelial cells. 
Therefore, if CFH5-7 was used as a drug it also might prevent relapses.  
There are only two main strategies to control Loa loa transmission rates in 
endemic countries - mass treatment of endemic communities or prevention of 
vector bites. The risk of adverse effects in areas coendemic for loiasis and 
onchocerciasis creates a strong need of novel control strategies (Padgett and 
Jacobsen, 2008). It remains to be studied whether CFH5-7 could decrease survival 
of Loa loa microfilariae in blood and whether this knowledge could assist in 
development of a safer way to prevent transmission of loiasis.  
The CFH5-7 fragment could also cause adverse effects because the domain seven 
of CFH interacts with heparin and malondialdehyde adducts (Blackmore et al., 
1996; Weismann et al., 2011). Therefore, it is theoretically also possible that CFH5-
7 fragment could prevent CFH interaction with host cells and thereby contribute to 
diseases such as AMD. The protective function of CFH5-7 against CFH binding 
microbes should be thoroughly investigated in further studies. 
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6 SUMMARY 
 
Binding of soluble complement regulators occurs both in vitro and in vivo and is a 
common complement evasion strategy of several microbial pathogens. In this 
thesis microfilariae of Loa loa were shown to bind CFH in vivo and the binding of 
the regulator was localized on the surface of the parasite. A large variety of 
bacteria have been shown to bind CFH via domains 5-7 or 19-20. S. pyogenes, the 
common causative agent of tonsillitis and erysipelas, was shown in this thesis to 
interact mainly with domains 5-7 of CFH. The ability to capture host CFH varies 
within different S. pyogenes emm types as well as within different isolates and the 
microbial induced complement activation is most likely dependent on the amount 
of CFH bound by the strain.  
While CFH binding by S. pyogenes seems to have an important role in microbial 
complement evasion and survival in blood, the AMD associated Y402H 
polymorphism could have an effect in genetic susceptibility of an individual to S. 
pyogenes infections via affecting to the binding affinity of CFH on the microbe. 
Since the domains 5-7 of CFH play an important role in binding of CFH by S. 
pyogenes the CFH5-7 fragment could be used in inhibiting survival of this 
bacterium in blood. Therefore CFH5-7 or a derivative of it that inhibits CFH binding 
to the bacteria might be used as a novel drug in treatment of S. pyogenes 
infections or infections caused by other CFH binding microbes. 
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